var title_f10_24_10624="Type 3 odontoid fracture";
var content_f10_24_10624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Odontoid fracture type III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type III odontoid fractures travel through the upper portion of the body of C2. They are mechanically unstable, since they allow the dens and the occiput to move as a unit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10624=[""].join("\n");
var outline_f10_24_10624=null;
var title_f10_24_10625="Taking the IP pedicle";
var content_f10_24_10625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Taking the infundibulopelvic pedicle during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10625=[""].join("\n");
var outline_f10_24_10625=null;
var title_f10_24_10626="Bile duct stone seen on cholangioscopy";
var content_f10_24_10626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bile duct stone seen on direct cholangioscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct cholangioscopy showing a large stone within the bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10626=[""].join("\n");
var outline_f10_24_10626=null;
var title_f10_24_10627="Stage IIIB NSCLC";
var content_f10_24_10627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Stage IIIB NSCLC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original, Anne Greene.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10627=[""].join("\n");
var outline_f10_24_10627=null;
var title_f10_24_10628="Gastric ulcer with adherent clot";
var content_f10_24_10628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Gastric ulcer with adherent clot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a gastric ulcer with an adherent clot (Forrest classification IIb).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10628=[""].join("\n");
var outline_f10_24_10628=null;
var title_f10_24_10629="Regulation thyroid hormone production";
var content_f10_24_10629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Regulation of thyroid hormone production",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thyrotropin-releasing hormone (TRH) increases the secretion of thyrotropin (TSH), which stimulates the synthesis and secretion of trioiodothyronine (T3) and thyroxine (T4) by the thyroid gland. T3 and T4 inhibit the secretion of TSH, both directly and indirectly by suppressing the release of TRH. T4 is converted to T3 in the liver and many other tissues by the action of T4 monodeiodinases. Some T4 and T3 is conjugated with glucuronide and sulfate in the liver, excreted in the bile, and partially hydrolyzed in the intestine. Some T4 and T3 formed in the intestine may be reabsorbed. Drug interactions may occur at any of these sites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10629=[""].join("\n");
var outline_f10_24_10629=null;
var title_f10_24_10630="Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information";
var content_f10_24_10630=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=see_link\">",
"     see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=see_link\">",
"     see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8084976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;;",
"     </li>",
"     <li>",
"      Asthmanefrin&trade; [OTC];",
"     </li>",
"     <li>",
"      Auvi-Q&trade;;",
"     </li>",
"     <li>",
"      EpiPen 2-Pak&reg;;",
"     </li>",
"     <li>",
"      EpiPen Jr 2-Pak&reg;;",
"     </li>",
"     <li>",
"      S2&reg; [OTC];",
"     </li>",
"     <li>",
"      Twinject&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8084977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;;",
"     </li>",
"     <li>",
"      Epi E-Z Pen&reg;;",
"     </li>",
"     <li>",
"      EpiPen&reg;;",
"     </li>",
"     <li>",
"      EpiPen&reg; Jr;",
"     </li>",
"     <li>",
"      Twinject&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a very bad allergic response.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used when the heart is not beating.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to epinephrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is used for an allergy emergency, go to the ER right away after using it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         EpiPen&reg;, EpiPen&reg; Jr:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read how to use before an emergency happens.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696214",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug for emergencies which may include insect stings or bites, food, drug, latex allergies, and ones caused by working out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep this drug with you at all times. You may want to keep extra ones at work, school, and home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Never put your fingers or hand over the tip.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take off safety release until ready to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution is not clear or if red flag is in window.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When you are ready to use, take the pen out of the case.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hold pen with tip down.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make a fist around the pen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull off safety release.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695252",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Jab straight into the outer thigh until it clicks and hold for 10 seconds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out tip and rub part where the shot was given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Get help now.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694574",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call the ER (emergency department). Do not drive yourself to the hospital.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695587",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put back in the storage case.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take it with you to the hospital.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Adrenalin&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only by a puffer (inhaler) or as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695219",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe in once. You may repeat in 1 minute if signs are not helped. Wait at least 3 hours before using again.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         EpiPen&reg;, EpiPen&reg; Jr:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Primatene&reg; Mist:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat or open flame.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Adrenalin&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11670 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-EC95FD50DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10630=[""].join("\n");
var outline_f10_24_10630=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676136\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029507\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029506\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029511\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029512\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029514\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029509\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029510\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029515\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029516\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/34/3620?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/59/4020?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_24_10631="Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors";
var content_f10_24_10631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10631/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10631/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10631/contributors\">",
"     Cornelia M Weyand, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10631/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10631/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10631/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10631/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/24/10631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of atherosclerotic coronary artery disease (CAD) is increased in patients with chronic inflammatory diseases affecting connective tissue, particularly those with systemic lupus erythematosus or rheumatoid arthritis (RA).",
"   </p>",
"   <p>",
"    The epidemiologic evidence, possible pathogenetic mechanisms, and clinical relevance of CAD in RA will be reviewed here. The impact of CAD on the management of RA; other cardiac manifestations of RA, including pericarditis, myocarditis, atrioventricular block, valvular regurgitation, embolic events, and rheumatoid nodules; and the general clinical manifestations of RA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Cardiac disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link&amp;anchor=H5#H5\">",
"     \"Rheumatoid nodules\", section on 'Cardiac nodules'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of premature death is observed in patients with rheumatoid arthritis (RA). This is largely due to cardiovascular disease, particularly coronary artery disease (CAD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H7#H7\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Comorbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported incidence and prevalence of CAD in patients with RA varies based upon the specific manifestations of the disease, the population evaluated,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the screening and diagnostic methods utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. A meta-analysis of 24 observational studies comprising 111,758 patients concluded that the risk of CAD mortality was 59 percent higher in patients with RA than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/8\">",
"     8",
"    </a>",
"    ]. Risk may be increased once symptoms develop and before patients meet formal classification criteria for the diagnosis of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the underlying mechanisms of pathogenesis of atherosclerosis are shared in patients with and without RA. Among the general population, it is increasingly clear that inflammation has a significant role in the development of coronary artery disease and that the innate and adaptive immune systems play an important role in the initiation and progression of atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is postulated that, in patients with RA, chronic inflammation may accelerate the progression of atherosclerosis, perhaps via the effects of cytokines; abnormal effector functions of T lymphocytes, macrophages, and dendritic cells; immune complexes; coagulation abnormalities; oxidative stress; or a combination of these factors. Some of these mechanisms may be [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in the endothelium due to circulating immune complexes, cytokines, or C-reactive protein",
"     </li>",
"     <li>",
"      A hypercoagulable state due to increased plasma levels of fibrinogen, von Willebrand factor, plasminogen activator inhibitor-1,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other acute phase reactants (eg, C-reactive protein) that correlate with the erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      Direct vascular injury, with depletion of circulating endothelial cell progenitors [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/15,19,20\">",
"       15,19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coupling of vascular wall and synovial inflammation. Abnormal adaptive immune responses, involving T cells and dendritic cells that have been described for the inflamed atherosclerotic plaque, are similar to those encountered in the inflamed synovial membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inflammation may worsen insulin resistance and may impair pancreatic beta cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These metabolic changes may contribute to accelerated atherosclerosis and to the higher incidence of ischemic heart disease characteristic of patients with diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H4873275#H4873275\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The constellation of abdominal obesity, hyperglycemia, dyslipidemia, and hypertension (referred to variously as the metabolic syndrome, syndrome X, and &ldquo;the deadly quartet&rdquo;) is associated with a higher risk of CAD and of cardiovascular morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .) The prevalence of the metabolic syndrome may be increased in patients with RA. This was illustrated in a study of 88 patients with early RA, 66 with longstanding RA, and 85 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The metabolic syndrome was present in 31 percent of patients with early RA, in 42 percent of those with longstanding RA, and in 11 percent of controls. In addition, those with the metabolic syndrome were more likely to have higher coronary calcification scores as detected by CT.",
"   </p>",
"   <p>",
"    In a study from the British Society for Rheumatology Biologics Register, the rates of myocardial infarction (MI) were examined in 8670 RA patients treated with tumor necrosis factor (TNF)-alpha inhibitors and were compared with the rate of MI among 2170 patients with active RA treated with disease-modifying antirheumatic drugs (DMARDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following adjustment for baseline cardiovascular risk factors, there was no reduction in the rate of MI in the TNF inhibitor cohort: incidence rate ratio 1.44 (95% CI 0.56-3.67).",
"     </li>",
"     <li>",
"      In the subset of TNF inhibitor-treated patients who responded to therapy within six months compared with those who did not, MI rates were 3.5 MIs per 1000 patient-years for responders, compared with 9.4 events per 1000 patient-years for non-responders.",
"     </li>",
"     <li>",
"      The adjusted incidence rate ratio for MI in responders versus non-responders was 0.36 (95% CI 0.19-0.69).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this study are consistent with the notion that inflammation plays an important role in MI among patients with RA, a view that is further supported by an autopsy study that compared coronary artery pathology of 41 deaths among patients with RA with 82 controls. Less atherosclerosis was present in those with RA, but more inflammation and unstable plaque were noted in those with RA versus the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/28\">",
"     28",
"    </a>",
"    ]. These findings are also consistent with the observation that elevated levels of TNF-alpha and interleukin (IL)-6 in patients with RA were associated with the severity of subclinical atherosclerosis, were identified by coronary artery calcification, and were independent of the Framingham risk score and diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing, persistent disease activity may be necessary to induce acceleration of atherosclerosis. In a study in Northern Sweden involving 79 patients with very early RA and 44 controls, prematurity of atherosclerosis was evaluated by measuring endothelial-dependent flow-mediated dilation and intima media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/29\">",
"     29",
"    </a>",
"    ]. There were no signs of atherosclerosis in patients with newly diagnosed RA when compared with controls, although serum markers suggestive of endothelial activation were significantly elevated in the patients.",
"   </p>",
"   <p>",
"    Another factor that may contribute to increased cardiovascular risk are autoantibodies to oxidized low density lipoprotein (anti-oxLDL), which were associated with &ldquo;subclinical atherosclerosis&rdquo; (eg, carotid artery intimal thickness) and C-reactive protein levels (and were inversely associated with high density lipoprotein levels) in a cohort of 140 patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary arteritis is a rare complication of rheumatoid vasculitis and is unlikely to be the cause of MI in the absence of other organ involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42407?source=see_link\">",
"     \"Epidemiology and pathogenesis of rheumatoid vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional risk factors for coronary artery disease in the general population include hypertension, cigarette smoking, diabetes, older age, and hypercholesterolemia. One study suggests that, with the exception of former cigarette smoking, these risk factors are not more prevalent in women with RA than in women without RA. This was best shown in an analysis of the Nurses&rsquo; Health Study in which the clinical risk factors for cardiovascular disease were compared in women with and without RA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/31\">",
"     31",
"    </a>",
"    ]. No significant differences between the two groups were observed for diabetes, hypertension, concurrent smoking, or dyslipidemia.",
"   </p>",
"   <p>",
"    However, in another study that included men and women, a significant difference in the prevalence of hypertension, diabetes, and prior or concurrent cigarette smoking was noted between those with RA and the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/32\">",
"     32",
"    </a>",
"    ]. Other studies have also noted an increased prevalence of traditional risk factors in patients with RA, particularly in those with longstanding disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. These data suggest that traditional risk factors do play a role in the increased risk of cardiovascular morbidity and mortality in RA.",
"   </p>",
"   <p>",
"    Exercise of even moderate degree has a protective effect against coronary heart disease and all-cause mortality. For a variety of reasons, many patients with RA exercise less than recommended amounts, thereby possibly enhancing the risk of heart disease. As an example, a study of 298 Swedish patients with rheumatoid arthritis identified 47 percent whose physical activity did not comply with public health recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Markers of increased systemic inflammation are also associated with an increased risk of coronary artery disease. The best studied of these markers in the general population and in those with RA is the acute phase reactant C-reactive protein (CRP). In the Nurses&rsquo; Health Study, for example, CRP levels were significantly higher in women with RA and heart disease versus those with heart disease but without RA (average CRP levels of 0.87 versus 0.34",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many other factors that may be associated with an increased risk of atherosclerosis in the general population. A few of these have also been evaluated in patients with RA. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with RA appear to have a significantly greater burden of atherosclerotic carotid plaques, suggesting the presence of generalized atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/5,35\">",
"       5,35",
"      </a>",
"      ]. The prevalence of carotid plaques as detected ultrasonographically correlates with the duration of RA [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/3,35\">",
"       3,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conflicting data exist concerning an increase in arterial intima-media thickness in patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/5,35,36\">",
"       5,35,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H10122160#H10122160\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial intima-media thickness'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coronary artery calcification noted on ultrafast CT scanning, a finding that is correlated with an increased risk of clinical and angiographic coronary atherosclerosis, is more prevalent in patients with established RA than in patients with early RA or healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/26,37,38\">",
"       26,37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of 603 adults with RA, those with rheumatoid factors receiving glucocorticoids appeared to be at greater risk for cardiovascular events than those patients who were seronegative [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/39\">",
"       39",
"      </a>",
"      ]. The mechanism of this effect is unknown. Others have proposed that the administration of glucocorticoids increases the risk of coronary artery disease via its effects on lipoprotein levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic use of selective cyclooxygenase (COX)-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs (NSAIDs) may increase the risk of MI, stroke, and sudden cardiac deaths. The adverse cardiovascular effects of COX-2 selective inhibitors and NSAIDs are discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A form of high density lipoprotein (HDL) cholesterol that is not protective against cardiovascular disease may be found in some patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. HDL with proinflammatory activity in vitro is found in patients with coronary heart disease and elevated HDL levels and is increased in patients with RA compared with healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/40\">",
"       40",
"      </a>",
"      ]. In a cross-sectional observational study, this form of HDL was significantly associated with active disease and joint injury in patients with RA and was inversely associated with use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10631/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H19#H19\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'High density lipoprotein'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an increased incidence of cardiovascular events, including myocardial infarctions and cardiac deaths, in patients with RA compared with the populations in which they live. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is postulated that the presence of chronic inflammation in RA may enhance the development of atherosclerosis. This may be the result of effects mediated by cytokines, immune complexes, elevated levels of C-reactive protein, endothelial dysfunction, or, rarely, coronary vasculitis. Abnormal functions of T cells, dendritic cells, and macrophages have been implicated in promoting inflammation and progression of atherosclerotic plaque formation, and similarities may exist between synovial and vascular inflammation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased risk of CAD related events does not appear to be mediated entirely through traditional risk factors for atherosclerosis. Use of antiinflammatory drugs such as glucocorticoids, NSAIDs, and COX-2 selective inhibitors may contribute to increased risk for coronary thrombosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the increased incidence of ischemic cardiac events in patients with RA, the prevalence of angina pectoris is lower than in the general population.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/1\">",
"      Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/2\">",
"      del Rinc&oacute;n ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/3\">",
"      Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/4\">",
"      Fischer LM, Schlienger RG, Matter C, et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/5\">",
"      Gonzalez-Juanatey C, Llorca J, Testa A, et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/6\">",
"      Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/7\">",
"      Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/8\">",
"      Avi&ntilde;a-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/9\">",
"      Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/10\">",
"      Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/11\">",
"      Holmqvist ME, Wedr&eacute;n S, Jacobsson LT, et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009; 60:2861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/12\">",
"      Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/13\">",
"      W&aring;llberg-Jonsson S, Cvetkovic JT, Sundqvist KG, et al. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/14\">",
"      W&aring;llberg-Jonsson S, Cederfelt M, Rantap&auml;&auml; Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000; 27:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/15\">",
"      Grisar J, Aletaha D, Steiner CW, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/16\">",
"      Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/17\">",
"      Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/18\">",
"      Rho YH, Chung CP, Oeser A, et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/19\">",
"      Yiu KH, Wang S, Mok MY, et al. Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatol 2010; 37:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/20\">",
"      Wrigley BJ, Lip GY, Shantsila E. Coronary atherosclerosis in rheumatoid arthritis: could endothelial progenitor cells be the missing link? J Rheumatol 2010; 37:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/21\">",
"      Niessner A, Sato K, Chaikof EL, et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/22\">",
"      Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/23\">",
"      Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/24\">",
"      Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/25\">",
"      Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/26\">",
"      Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/27\">",
"      Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/28\">",
"      Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/29\">",
"      S&ouml;dergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010; 12:R158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/30\">",
"      Peters MJ, van Halm VP, Nurmohamed MT, et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008; 35:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/31\">",
"      Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50:3444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/32\">",
"      Bhatia GS, Sosin MD, Patel JV, et al. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden? J Am Coll Cardiol 2006; 47:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/33\">",
"      Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8:R186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/34\">",
"      Eurenius E, Stenstr&ouml;m CH. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum 2005; 53:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/35\">",
"      Roman MJ, Moeller E, Davis A, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/36\">",
"      Del Rinc&oacute;n I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/37\">",
"      Kao AH, Wasko MC, Krishnaswami S, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 2008; 102:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/38\">",
"      Kao AH, Krishnaswami S, Cunningham A, et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol 2008; 35:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/39\">",
"      Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/40\">",
"      McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10631/abstract/41\">",
"      Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60:2870.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7481 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10631=[""].join("\n");
var outline_f10_24_10631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42407?source=related_link\">",
"      Epidemiology and pathogenesis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_24_10632="Excitation-contraction coupling in myocardium";
var content_f10_24_10632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Excitation-contraction coupling in myocardium",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10632/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10632/contributors\">",
"     Timothy W Smith, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10632/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10632/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10632/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10632/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/24/10632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excitation-contraction (E-C) coupling refers to the series of events that links the action potential (excitation) of the muscle cell membrane (the sarcolemma) to muscular contraction. Although E-C coupling in myocardium is similar in many ways to skeletal muscle and smooth muscle, there are also critical differences. The cyclical nature of cardiac contraction and the importance of myocardial relaxation to cardiac pump function requires that any discussion of E-C coupling also consider the events terminating the muscle twitch as an integral part of the subject. Modulation of muscular function is said to affect inotropy (the speed and strength of muscular contraction) or lusitropy (the ability of the muscle to relax). Increased knowledge about E-C coupling has been a key to understanding both the inotropic and lusitropic states, and it continues to be useful in developing improved therapy for heart failure and cardiogenic shock.",
"   </p>",
"   <p>",
"    This is a brief review of cardiac excitation (the myocardial action potential) followed by a description of muscular contraction. E-C coupling is then presented as the transduction of a membrane signal (the action potential) to an intracellular effector (the contractile apparatus) by way of a second messenger (intracellular free calcium [Ca2+]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYOCARDIAL ACTION POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resting membrane potential of the myocardial cell is cell interior negative (-90 mV), and is primarily determined by the ratio of intracellular-to-extracellular potassium as predicted by the Nernst equation. The action potential is a temporary depolarization of the membrane. It is caused by transient changes in membrane conductance of several charged ions, especially sodium, due to the opening and closing of ion-specific channels in the membrane. This process can be summarized as follows (",
"    <a class=\"graphic graphic_figure graphicRef71390 \" href=\"UTD.htm?15/55/16253\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61058 \" href=\"UTD.htm?31/46/32481\">",
"     movie 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid depolarization (phase 0) occurs when the resting cell is brought to threshold, leading sequentially to activation or opening of voltage-dependent sodium channels, rapid sodium entry into the cells down a favorable concentration gradient, and a cell interior positive potential that can approach +45 mV. The marked depolarization results in voltage-dependent inactivation of the sodium channels and cessation of the inward sodium flux. Calcium channels also open during depolarization but the onset of the inward calcium flux is much slower.",
"     </li>",
"     <li>",
"      Phase 1 repolarization is primarily due to inactivation of the sodium channels with abolition of the inward sodium current.",
"     </li>",
"     <li>",
"      This is followed by a plateau in phase 2 in which continued slow calcium entry into the cell balances the electrical effect of potassium loss, as more voltage-dependent potassium channels open up. The voltage in the plateau phase is sufficient to maintain the sodium channels in the closed, inactive state.",
"     </li>",
"     <li>",
"      The cessation of the calcium current and a further increase in potassium current leads to rapid completion of repolarization with return to the resting potential (phase 3).",
"     </li>",
"     <li>",
"      Normal cell sodium and potassium activities are restored by the Na-K-ATPase pump, which extrudes the sodium that entered during depolarization and pumps in the potassium that was lost during repolarization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The action potential at a specific region of membrane is conducted along the membrane and depolarizes neighboring regions, causing their thresholds to be reached, thereby generating another local action potential. This process conducts the action potential as an electrical signal along the muscle fibers of the heart. Linear propagation of the action potential occurs rapidly because the myocytes along muscle fibers are electrically continuous. An action potential can also cause the depolarization of a neighboring fiber, and the electrical impulse occurs as a \"wave\" through the heart.",
"   </p>",
"   <p>",
"    The regulation and process of depolarization is somewhat different in pacemaker cells. Each normal heartbeat is initiated by pacemaker cells in the sinoatrial node, generating a slow, calcium ion mediated action potential. These cells manifest continuous variability of their resting membrane potential in a cyclical fashion (ie, spontaneous automaticity), generating an action potential every time the resting potential reaches threshold (-40 mV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MUSCLE CONTRACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contractile apparatus of myocytes is the myofibril, a cylindrical structure composed of thick and thin filaments arranged longitudinally parallel within the myofibril.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The thin filament is composed of two strands of F-actin wound around each other. Each strand of F-actin is composed of globular G-actin monomers, polymerized in a linear pattern.",
"     </li>",
"     <li>",
"      The thick filament is composed of myosin, a molecule with a long \"tail\" section made up of two helices twisted around one another, each attached to a roughly globular \"head.\" There is a hinge point between the tail and the head that allows the head segment of the molecule to fold back upon itself. The thick filament, then, is an association of all the tail portions of many myosin molecules with the head portions protruding toward the adjacent thin filaments.",
"     </li>",
"     <li>",
"      The sarcomere is the functional unit of the myofibril. Each sarcomere is about 2&micro;m in length, and there are many copies throughout the length of the myofibril. The sarcomere is bounded at each end by the Z-bands, which run perpendicular to the thick and thin filaments and to which the thin filaments are attached. In the relaxed state, the thin filaments extend from the Z-band toward the center of the sarcomere (",
"      <a class=\"graphic graphic_figure graphicRef63547 \" href=\"UTD.htm?43/45/44765\">",
"       figure 2",
"      </a>",
"      ). The gap in the center between the thin filaments is the H-zone. The thick filaments are interspersed between the thin filaments (parallel to them) in the center of the sarcomere, crossing the H-zone. During contraction, the thick filaments \"pull\" the thin filaments and the Z-bands toward the center of the sarcomere. Both the H-zone and the sarcomere itself shorten in length during contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscular contraction is the shortening of the myofibrils that occurs when the thick and thin filaments slide past one another (",
"    <a class=\"graphic graphic_figure graphicRef63547 \" href=\"UTD.htm?43/45/44765\">",
"     figure 2",
"    </a>",
"    ). The sliding of the thick and thin filaments is thought to occur by repetitive binding of the myosin heads to actin, flexion of the myosin molecules at their hinge points, release of the binding between the molecules, and relaxation of the myosin molecule prior to binding the actin again. This repetitive motion is referred to as cross-bridge cycling. In this way the thick filament is thought to \"ratchet\" itself past the thin filament.",
"   </p>",
"   <p>",
"    The mechanism of cross-bridge cycling is complex, but may be usefully modeled by a four-step process requiring the presence of ATP (adenosine triphosphate) (",
"    <a class=\"graphic graphic_figure graphicRef51291 \" href=\"UTD.htm?18/40/19074\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/1\">",
"     1",
"    </a>",
"    ]. Beginning with actin and myosin in the dissociated state, the myosin head is bound to an ATP molecule.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first step is the hydrolysis of the high energy phosphate bond of ATP to form ADP (adenosine diphosphate) and Pi (inorganic phosphate), thereby energizing the myosin molecule.",
"     </li>",
"     <li>",
"      The second step is formation of the active actin-myosin complex (the cross-bridge).",
"     </li>",
"     <li>",
"      The third step is dissociation of ADP and Pi from the myosin head, which allows the flexion of the myosin at its hinge point. The myosin head remains bound and flexed until the fourth step.",
"     </li>",
"     <li>",
"      The fourth step is binding of ATP, which allows dissociation of the actin and myosin returning to the beginning of the cycle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, while the hydrolysis of ATP supplies the energy for the flexion of the myosin molecule, it is the binding of ATP that allows the dissociation of the myosin head from actin. (This is also true in skeletal muscle, accounting for the phenomenon of rigor mortis, the stiffening of skeletal muscle after death, due to lack of ATP to bind the myosin in the flexed state.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of tropomyosin and troponins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the resting state, the interaction of the thick and thin filaments is physically blocked by the presence of the protein tropomyosin, which lies in the groove of the thin filament formed by the two F-actin strands. Tropomyosin is closely associated with three other proteins, troponin I, troponin T, and troponin C. It is the troponin-tropomyosin complex that regulates the interaction of the thick and thin filaments and therefore muscular contraction. Troponin C has a calcium binding site that, when occupied by a calcium ion, causes a conformational change in the troponin-tropomyosin complex (",
"    <a class=\"graphic graphic_figure graphicRef67388 \" href=\"UTD.htm?14/21/14673\">",
"     figure 4",
"    </a>",
"    ). This change moves the tropomyosin molecule from its resting position, which makes the myosin binding site accessible to the myosin head. Cross-bridge cycling then begins and the myofibrils forcefully shorten until calcium is removed from troponin C and tropomyosin returns to its resting position, blocking actin and myosin binding.",
"   </p>",
"   <p>",
"    The other troponin proteins also contribute to this process. Troponin I is an inhibitory protein which inhibits the ATPase of actomyosin and also modulates calcium binding to troponin C. Troponin T serves to attach the troponin complex to actin and tropomyosin; in the relaxed state, it blocks the actin-myosin binding site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SIGNAL TRANSDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;E-C coupling can be viewed as the transduction of a cell membrane signal (the action potential) to stimulate the action of an effector in the cell (myofibril contraction). The second messenger in this transduction system is calcium. High concentrations of calcium within the cell are very cytotoxic, stimulating proteases and lipases whose actions ultimately result in cell death. As a result, nearly all cells are highly adapted to maintain very low levels of intracellular free calcium.",
"   </p>",
"   <p>",
"    The low cell calcium concentration has been put to use by several cell types, allowing rapid influx of calcium to serve as a trigger for the action of an intracellular effector [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/1\">",
"     1",
"    </a>",
"    ]. The calcium transient must be fleeting in order to ensure the long-term health of the cell. In mammalian myocardial cells, for example, the resting intracellular calcium concentration is in the range of 100 to 300",
"    <span class=\"nowrap\">",
"     nmol/L.",
"    </span>",
"    With each action potential, intracellular free calcium rises rapidly by a factor of approximately 10,000 to the millimolar range. At this concentration, calcium binds to troponin C, allowing actin-myosin cross-bridge formation and myofibril shortening. The rapid removal of free calcium from the cytoplasm is also critical, not only to relaxation of the myocardium, but to the health of the cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     The calcium transient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thus, the generation, modulation, and termination of the intracellular calcium transient is the essence of E-C coupling. The calcium transient is initiated by the entry of calcium into the cell via voltage-activated calcium-specific membrane channels. These are among the channels that are opened transiently during the action potential. The favorable and large electrochemical gradient (low cell calcium concentration, cell interior electronegative) provides a strong driving force for the influx of calcium.",
"   </p>",
"   <p>",
"    However, calcium influx through these sarcolemmal channels is not the major source of calcium producing the calcium transient. Instead, a relatively small influx of calcium triggers the release of a much larger quantity of calcium from the primary intracellular store of calcium, the sarcoplasmic reticulum (SR), through SR calcium release channels.",
"   </p>",
"   <p>",
"    The sarcolemmal calcium channel and the SR calcium release channel are different entities. While the calcium channels of the sarcolemma (known as L-type calcium channels) are activated by voltage and blocked by the dihydropyridines (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ), the SR calcium channels are stimulated to open by the binding of calcium itself on the cytoplasmic side of the membrane.",
"   </p>",
"   <p>",
"    The rise in intracellular free calcium concentration is a very short-lived phenomenon, lasting approximately 100 msec. The excess calcium must be removed from the cytoplasm in order to stop the process of actin-myosin cross-bridge cycling and to permit the myocardium to relax. In the steady state, the same amount of calcium that entered the cell through the sarcolemma from the extracellular space must be extruded from the cell. Similarly, the amount of calcium that was released from SR must be re-sequestered in the SR. In both cases the transport of calcium is against the electrochemical gradient, requiring active, energy dependent transport processes, and ultimately ATP.",
"   </p>",
"   <p>",
"    Calcium efflux to the extracellular space is mediated by two different transporters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sarcolemmal calcium pump, which is a membrane protein that transports its substrate (calcium) against the electrochemical gradient using the energy obtained by hydrolysis of a high energy phosphate bond of ATP.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       Na+/Ca2+",
"      </span>",
"      exchanger, a secondary active transporter that uses the inward energy in the electrochemical sodium gradient to drive the extrusion of calcium against its gradient. The sodium gradient is established by the action of the Na-K-ATPase pump, which maintains a low cell sodium concentration and a cell interior negative potential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     Na+/Ca2+",
"    </span>",
"    exchange mechanism has a high capacity for calcium, but a low affinity. It is therefore most efficient at calcium efflux when the intracellular calcium is high. Conversely, the calcium pump has a high affinity for calcium but a low capacity. Its primary role is to remove the remaining calcium above the resting concentration after intracellular calcium has decreased from its peak, when the",
"    <span class=\"nowrap\">",
"     Na+/Ca2+",
"    </span>",
"    exchanger is working less efficiently.",
"   </p>",
"   <p>",
"    Uptake of calcium into the SR is mediated by a calcium pump protein located in the SR membrane. The SR calcium pump is another member of the family of transporters that derives its energy from hydrolysis of ATP. Calcium is sequestered in the SR at high concentrations. Much of this calcium is bound to proteins, such as calsequestrin 2, which concentrate the calcium in the terminal cisternae of the SR. From this site, calcium is readily available for release into the cytoplasm during the next contraction cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MODULATION OF MYOCARDIAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the central role of the calcium transient, modulation of either the calcium transient or the response of the contractile apparatus to the calcium transient will also affect contractility. Such modulation may occur as a response to a physiologic need for increased cardiac output. On the other hand, failure of proper control of E-C coupling may be the etiology of pathologic states, a setting in which pharmacologic modification of E-C coupling may be an important component to therapy.",
"   </p>",
"   <p>",
"    This section will discuss some of the ways in which modulation of E-C coupling can change myocardial function. Figures 5 and 6 are representations of the regulation of sarcolemma and sarcoplasmic reticulum function (",
"    <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62842 \" href=\"UTD.htm?8/14/8417\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Alteration of the calcium transient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of the calcium transient may be increased in several ways. The simplest is making more calcium available to the cell from the extracellular space. It must be remembered that the extracellular calcium is not the primary source of the calcium transient. However, increased extracellular calcium raises the transsarcolemmal gradient, increasing the influx of calcium in each cycle of calcium channel opening. This change in intracellular calcium gradually increases the SR calcium store, and therefore increases the magnitude of the calcium transient until a new steady state between sarcolemmal influx and efflux is established. Increasing extracellular calcium is effective in vitro, but has little application in vivo. The sophisticated systems for regulating plasma free calcium make it difficult to significantly change the transsarcolemmal calcium gradient for an extended period of time.",
"   </p>",
"   <p>",
"    Another way to increase cell calcium is to inhibit efflux by increasing the cell sodium concentration, thereby diminishing the activity of",
"    <span class=\"nowrap\">",
"     Na+/Ca2+",
"    </span>",
"    exchange. This is the mechanism by which digitalis, via inhibition of the Na-K-ATPase pump affects contractility (",
"    <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"     figure 5",
"    </a>",
"    ) (see below).",
"   </p>",
"   <p>",
"    The amount of calcium available for SR sequestration can also be increased by raising cycle frequency. The duration of contraction (systole) is much less flexible than the duration of relaxation (diastole). (It is a well known phenomenon that, as the heart rate increases, diastole shortens much more than systole.) Thus, calcium efflux for each cycle cannot match the calcium influx as the rate increases. The amount of calcium in the cell increases until a new steady state is reached. The gradually increasing force of contractility with an increase in contraction frequency is known as the treppe or Bowditch positive staircase.",
"   </p>",
"   <p>",
"    Extrasystoles have a similar effect. While the force of a premature systole may not be great, there is an \"extra\" opportunity for calcium to enter the cell. The contraction following an extrasystole is significantly more forceful than a contraction of typical cycle (a phenomenon called postextrasystolic potentiation). The extra action potential allows another opportunity for calcium influx via the voltage activated calcium channels (and also decreases calcium efflux via the",
"    <span class=\"nowrap\">",
"     Na+/Ca2+",
"    </span>",
"    exchanger). More intracellular calcium is now available to bind to troponin C and activate the myofibrils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Digitalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac glycosides (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) are thought to act by indirectly increasing the availability of intracellular calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/2\">",
"     2",
"    </a>",
"    ]. The proposed mechanism begins with the primary action of these drugs, inhibition of the Na-K-ATPase pump. This transporter is the primary route of sodium efflux from the cell. Inhibition of the pump sequentially increases intracellular sodium, diminishes the activity of the",
"    <span class=\"nowrap\">",
"     Na+/Ca2+",
"    </span>",
"    exchanger (since there is a less favorable inward gradient for sodium), and, because of a lower rate of extrusion, enhances the amount of intracellular calcium available for sequestration and use in E-C coupling (",
"    <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cyclic adenosine monophosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic AMP is the most important modulator of intracellular calcium handling, making it the most important second messenger in E-C coupling after calcium itself. Cyclic AMP is formed from ATP by the enzyme adenylyl cyclase. The activity of adenylyl cyclase is stimulated by the beta-adrenergic receptor (via a G-protein) when occupied by beta agonist (catecholamine) (",
"    <a class=\"graphic graphic_figure graphicRef53118 \" href=\"UTD.htm?20/34/21025\">",
"     figure 5",
"    </a>",
"    ). Cyclic AMP is metabolized in the cell by phosphodiesterases, inhibition of which can increase cardiac contractility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyclic AMP activates cyclic AMP-dependent protein kinases, which catalyze the phosphorylation of their specific target proteins and modify the function of these proteins. The effects of increasing cyclic AMP illustrate the importance of the interaction between inotropy and lusitropy in increasing stroke volume, which is the ultimate function of beta adrenergic stimulation of the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyclic AMP mediates the phosphorylation of the sarcolemmal calcium channel, which results in an increase in the conductance of the channel. As a result, more calcium can enter the cell and strengthen the force of contraction.",
"     </li>",
"     <li>",
"      Cyclic AMP stimulates protein kinase A (PKA), which phosphorylates the protein phospholamban, which, when not phosphorylated, inhibits the SR calcium pump [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/4\">",
"       4",
"      </a>",
"      ]. Phosphorylation removes this inhibitory activity; this is an inotropic effect, since it enhances intracellular calcium stores and increases the magnitude of the calcium transient. Experimental studies and preliminary human data suggest that gene therapy aimed at reducing phospholamban activity can reduce heart failure progression in association with increased SR calcium pump activity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=see_link\">",
"       \"Genetic and cellular therapy in heart failure and myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasing SR calcium pump activity also has a lusitropic effect since the increased rate of sequestration of calcium into the SR shortens the duration of the calcium transient. This has the effect of removing calcium from its troponin C binding site and halting actin myosin cross-bridge cycling more quickly. Systole is shortened, leaving time in the cycle for the heart to relax and fill with blood in preparation for the next systole. Increased filling increases stroke volume and enhances the force of contraction via the Frank-Starling mechanism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another lusitropic effect of cyclic AMP is achieved by phosphorylation of the Na-K-ATPase pump, which increases its turnover rate, thereby enhancing sodium efflux. The ensuing fall in cell sodium concentration increases the ability of the Na+",
"      <span class=\"nowrap\">",
"       /Ca2+",
"      </span>",
"      exchanger to extrude calcium from the cell. Once again, the effect is to shorten the duration and decrease the magnitude of the calcium transient and hasten myocardial relaxation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Phosphatidylinositol pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another second messenger pathway is involved in calcium handling. Inositol 4,5-triphosphate (IP3) and diacylglycerol (DAG) are the products of hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) (",
"    <a class=\"graphic graphic_figure graphicRef70144 \" href=\"UTD.htm?19/31/19966\">",
"     figure 7",
"    </a>",
"    ). Hydrolysis of PIP2 is catalyzed by the enzyme phospholipase C. Phospholipase C activity is stimulated (via a G-protein) by the binding of an alpha-adrenergic agonist to the alpha adrenergic receptor. IP3 stimulates the calcium release channel of the SR, increasing the magnitude of the calcium transient, which in turn increases contractile force [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are specific receptors for angiotensin II in myocardium. Angiotensin II is a potent vasoconstrictor which also acts directly on the heart. There is, in addition, strong evidence for local secretion of renin and angiotensinogen by the heart itself (ie, for the local formation of angiotensin II) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Angiotensin II affects heart rate and contractility and, over the long term, growth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. It has been proposed that angiotensin II is an important determinant of the development of left ventricular hypertrophy in patients with hypertension, which could explain the enhanced ability of angiotensin converting enzyme inhibitors to cause regression of hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the data suggest that angiotensin II enhances contractility by a cyclic AMP mediated mechanism. However, not all studies have shown an inotropic effect of angiotensin II. An in vitro study of human myocardium, for example, found that angiotensin II increased contractility of atrial but not ventricular myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Alteration of the myofibril response to calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modification of contractility without changing the calcium transient requires modification of the myofibril response to free calcium. The affinity of the troponin C binding site or the response of the myofibrils to a given level of calcium binding may be changed.",
"   </p>",
"   <p>",
"    Cyclic AMP also plays a role in this type of modification of E-C coupling. Cyclic AMP mediates the phosphorylation of troponin I. This decreases the affinity of troponin C for calcium, which is a lusitropic effect. The lower affinity for calcium permits faster sequestration in the SR. Once again, diastolic relaxation and ventricular filling, stimulated by beta 1 and beta 2- adrenergic activity and mediated by cyclic AMP, may be seen as a means of increasing stroke volume and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/10\">",
"     10",
"    </a>",
"    ]. Though the reduction in affinity for calcium has a negative inotropic effect, this is overcome in systole by the increase in calcium available. Cyclic AMP also has the positively inotropic effect of enhancing the rate of actin-myosin cross-bridge cycling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The alpha",
"    <span class=\"nowrap\">",
"     adrenergic/PIP2",
"    </span>",
"    pathway also appears to affect the calcium affinity of the contractile apparatus. IP3 and DAG increase the binding of calcium to its receptor, a positive inotropic effect. This appears to be mediated by phosphorylation by protein kinase C, although the target for phosphorylation is not yet known [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intracellular pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been known that acidosis has a negative inotropic influence on the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. An acid environment affects each stage of EC coupling, including the action potential and the Ca2+ transient. An important site of action appears to be on the sensitivity of the contractile apparatus to calcium. Acidosis markedly decreases calcium binding to troponin C by increasing the inhibitory effect of troponin I and to a lesser degree by a direct effect on the affinity of troponin C for calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal regulation of intracellular calcium plays a prominent role in heart failure. In an animal model of myocardial infarction, the calcium current influx is less able to trigger the release of calcium from the SR, an important factor contributing to the development of contractile dysfunction and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring calcium transients in vitro has shown that patients with cardiomyopathies have abnormal regulation of intracellular calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/17\">",
"     17",
"    </a>",
"    ]. The reduced intracellular calcium transient is likely due to a decreased SR calcium uptake and content [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/18\">",
"     18",
"    </a>",
"    ]. Impaired regulation of the calcium transient and of the maintenance of a low resting intracellular calcium can cause both poor contractile function in systole and poor relaxation in diastole [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It has been estimated, for example, that up to 40 percent of patients with heart failure have normal systolic function, suggesting diastolic dysfunction as the cause of failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One possible cause of abnormal calcium regulation in CHF is impaired production of intracellular cyclic AMP. This is suggested by the relatively poor response of diseased myocardium to inotropic drugs which, in normal myocardium, increase cyclic AMP levels by inhibiting its breakdown by phosphodiesterase. Furthermore, pharmacologic stimulation of cyclic AMP production via stimulation of adenylyl cyclase with forskolin can potentiate the effects of phosphodiesterase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since intracellular calcium appears so important in both systolic and diastolic dysfunction, drugs that modify intracellular calcium are potential candidates for heart failure therapy. This is an area of active investigation, although the results at the clinical level have been somewhat disappointing. Inotropic agents may actually increase or, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , have no effect on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/24\">",
"     24",
"    </a>",
"    ], while drugs that decrease cardiac work, particularly the ACE inhibitors, prolong survival by slowing the rate of deterioration of myocardial function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inotropic drugs that modulate calcium handling may be reasonably divided into two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those that act by increasing cyclic AMP, including the beta adrenergic agonists (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      , norepinephrine, epinephrine, dopamine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ), the phosphodiesterase inhibitors such as inamrinone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Those that act more directly on calcium movements into and out of the sarcoplasm, such as digitalis. On the other hand, calcium channel blockers, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (and other dihydropyridines) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      have negative inotropic effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another potential mechanism for an inotropic agent is increasing the sensitivity of the myofibril response to the calcium transient, thereby increasing contractility at a given concentration of calcium. Pimobendan is an agent that sensitizes the contractile proteins to calcium and has been shown to have an inotropic effect as well as a positive clinical effect on patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10632/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Familial hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in patients with familial forms of hypertrophic cardiomyopathy illustrate the importance of proper function of the different steps in excitation-contraction coupling. Defects in several different contractile protein genes have been identified in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16641124\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linear propagation of the action potential occurs rapidly because the myocytes along muscle fibers are electrically continuous. An action potential can also cause the depolarization of a neighboring fiber, and the electrical impulse occurs as a \"wave\" through the heart. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Myocardial action potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The contractile apparatus of myocytes is the myofibril, a cylindrical structure composed of thick and thin filaments arranged longitudinally parallel within the myofibril. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Muscle contraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscular contraction is the shortening of the myofibrils that occurs when the thick and thin filaments slide past one another (",
"      <a class=\"graphic graphic_figure graphicRef63547 \" href=\"UTD.htm?43/45/44765\">",
"       figure 2",
"      </a>",
"      ). The sliding of the thick and thin filaments is thought to occur by repetitive binding of the myosin heads to actin, flexion of the myosin molecules at their hinge points, release of the binding between the molecules, and relaxation of the myosin molecule prior to binding the actin again. This repetitive motion is referred to as cross-bridge cycling. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the resting state, the interaction of the thick and thin filaments is physically blocked by the presence of the protein tropomyosin, which lies in the groove of the thin filament formed by the two F-actin strands. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Role of tropomyosin and troponins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      E-C coupling can be viewed as the transduction of a cell membrane signal (the action potential) to stimulate the action of an effector in the cell (myofibril contraction). The second messenger in this transduction system is calcium. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Signal transduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The generation, modulation, and termination of the intracellular calcium transient is the essence of E-C coupling. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'The calcium transient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cyclic AMP is the most important modulator of intracellular calcium handling, making it the most important second messenger in E-C coupling after calcium itself. Cyclic AMP is formed from ATP by the enzyme adenylyl cyclase. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cyclic adenosine monophosphate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modification of contractility without changing the calcium transient requires modification of the myofibril response to free calcium. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Alteration of the myofibril response to calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal regulation of intracellular calcium plays a prominent role in heart failure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since intracellular calcium appears so important in both systolic and diastolic dysfunction, drugs that modify intracellular calcium are potential candidates for heart failure therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Katz AM. Mechanism and control of the cardiac contractile process. In: Physiology of the Heart, Raven Press, New York 1992. p.178.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/2\">",
"      Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/3\">",
"      Katz AM. Cyclic adenosine monophosphate effects on the myocardium: a man who blows hot and cold with one breath. J Am Coll Cardiol 1983; 2:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/4\">",
"      Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med 2000; 32:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/5\">",
"      Scholz J, Schaefer B, Schmitz W, et al. Alpha-1 adrenoceptor-mediated positive inotropic effect and inositol trisphosphate increase in mammalian heart. J Pharmacol Exp Ther 1988; 245:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/6\">",
"      Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/7\">",
"      Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/8\">",
"      Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/9\">",
"      Holubarsch C, Hasenfuss G, Schmidt-Schweda S, et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions. Circulation 1993; 88:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/10\">",
"      Kaumann A, Bartel S, Molenaar P, et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999; 99:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/11\">",
"      Hoh JF, Rossmanith GH, Kwan LJ, Hamilton AM. Adrenaline increases the rate of cycling of crossbridges in rat cardiac muscle as measured by pseudo-random binary noise-modulated perturbation analysis. Circ Res 1988; 62:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/12\">",
"      Puceat M, Clement O, Lechene P, et al. Neurohormonal control of calcium sensitivity of myofilaments in rat single heart cells. Circ Res 1990; 67:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/13\">",
"      Orchard CH, Kentish JC. Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/14\">",
"      Poole-Wilson PA. Regulation of intracellular pH in the myocardium; relevance to pathology. Mol Cell Biochem 1989; 89:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/15\">",
"      Solaro RJ, el-Saleh SC, Kentish JC. Ca2+, pH and the regulation of cardiac myofilament force and ATPase activity. Mol Cell Biochem 1989; 89:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/16\">",
"      G&oacute;mez AM, Guatimosim S, Dilly KW, et al. Heart failure after myocardial infarction: altered excitation-contraction coupling. Circulation 2001; 104:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/17\">",
"      Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/18\">",
"      Hobai IA, O'Rourke B. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation 2001; 103:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/19\">",
"      Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 1991; 325:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/20\">",
"      Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med 1991; 325:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/21\">",
"      Soufer R, Wohlgelernter D, Vita NA, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985; 55:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/22\">",
"      Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987; 75:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/23\">",
"      N&auml;bauer M, B&ouml;hm M, Brown L, et al. Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts. Eur J Clin Invest 1988; 18:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/24\">",
"      Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10632/abstract/25\">",
"      Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992; 85:942.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3451 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10632=[""].join("\n");
var outline_f10_24_10632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16641124\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYOCARDIAL ACTION POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MUSCLE CONTRACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of tropomyosin and troponins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SIGNAL TRANSDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      The calcium transient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MODULATION OF MYOCARDIAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Alteration of the calcium transient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Digitalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cyclic adenosine monophosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Phosphatidylinositol pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Alteration of the myofibril response to calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intracellular pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Familial hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16641124\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3451|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/55/16253\" title=\"figure 1\">",
"      Myocardial action potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/45/44765\" title=\"figure 2\">",
"      Sarcomere function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/40/19074\" title=\"figure 3\">",
"      Actin myosin interaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/21/14673\" title=\"figure 4\">",
"      Troponin tropomyosin complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/34/21025\" title=\"figure 5\">",
"      Regulation sarcolemma function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/14/8417\" title=\"figure 6\">",
"      Regulation SR function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/31/19966\" title=\"figure 7\">",
"      Phosphatidylinositol turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3451|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/46/32481\" title=\"movie 1\">",
"      Generation of the myocardial action potential",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=related_link\">",
"      Genetic and cellular therapy in heart failure and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_24_10633="Principles of abdominal wall closure";
var content_f10_24_10633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of abdominal wall closure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10633/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10633/contributors\">",
"     Jason S Mizell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10633/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10633/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10633/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10633/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/24/10633/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal abdominal wound closure provides strength and a barrier to infection. In addition, the closure should be efficient, performed without tension or ischemia, comfortable for the patient, and aesthetic.",
"   </p>",
"   <p>",
"    Closure of abdominal incisions will be reviewed here. Incisions for opening the abdomen, wound healing, and wound complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MATERIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds have less than 5 percent of normal tissue strength during the first postoperative week, thus wound security is dependent solely upon the suture closure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H5#H5\">",
"     \"Closure of skin wounds with sutures\", section on 'Suture materials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2858619\">",
"    <span class=\"h3\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suture should be the smallest caliber that is strong enough to reapproximate the tissue and keep the wound intact during normal postoperative activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/1\">",
"     1",
"    </a>",
"    ]. Suture caliber is one factor in minimizing the amount of foreign material in the wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2858611\">",
"    <span class=\"h3\">",
"     Synthetic versus natural",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical element of effective closure is the choice of suture material. Sutures can be made from natural fibers or produced synthetically. Natural suture materials include silk, linen, and catgut (dried and treated bovine or ovine intestine). Synthetic sutures are made from a variety of textiles such as nylon or polyester, formulated specifically for surgical use.",
"   </p>",
"   <p>",
"    Advantages of synthetic suture over natural fibers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater uniformity",
"     </li>",
"     <li>",
"      Greater tensile strength",
"     </li>",
"     <li>",
"      Longer duration of support during wound healing",
"     </li>",
"     <li>",
"      Greater wound security",
"     </li>",
"     <li>",
"      Less inflammatory response [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Less theoretical risk of disease transmission from animals (eg, Bovine Spongiform Encephalopathy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Absorbable versus nonabsorbable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absorbable synthetic sutures are made from polyglycolic acid or other glycolide polymers. Absorbable suture is generally degraded within days to weeks, although delayed absorbable suture may retain strength for up to two months (",
"    <a class=\"graphic graphic_table graphicRef66977 \" href=\"UTD.htm?32/43/33467\">",
"     table 1",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65396 \" href=\"UTD.htm?24/47/25340\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Synthetic absorbable sutures generally produce less tissue reaction than natural absorbable sutures (eg, plain gut, chromic catgut), which is thought to be due to the nature of suture breakdown. Synthetic absorbable sutures are broken down by hydrolysis, whereas natural absorbable sutures are degraded by proteolysis. &nbsp;",
"   </p>",
"   <p>",
"    Common types of synthetic absorbable sutures and their in-vivo half-lives are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyglactin 910 (Vicryl&trade;) &ndash; two weeks",
"     </li>",
"     <li>",
"      Polyglycolic acid (Dexon&trade;) &ndash; two weeks",
"     </li>",
"     <li>",
"      Poliglecaprone (Monocryl&trade;) &ndash; two weeks",
"     </li>",
"     <li>",
"      Polydioxanone (PDS&trade;) &ndash; three weeks",
"     </li>",
"     <li>",
"      Polyglyconate (Maxon&trade;) &ndash; six weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonabsorbable suture typically maintains tensile strength for more than two months, and many synthetics remain in the incision permanently. In theory, nonabsorbable sutures made of natural fibers, such as cotton, linen, and silk, remain permanently in the wound, although, in reality, they gradually disappear.",
"   </p>",
"   <p>",
"    Synthetic nonabsorbable sutures generate similar tensile strength and tissue reaction as synthetic absorbable sutures, but they have longer wound security (300 days or more). Some examples of this type of suture include polyamide (Nylon), polypropylene (Prolene&trade;), polybutester (Novafil&trade;), and polyester (Mersilene&trade;).",
"   </p>",
"   <p>",
"    As a result of their increased and prolonged tensile strength, it might be predicted that nonabsorbable sutures should decrease the risk of wound dehiscence and hernia, as compared with absorbable sutures. However, the superiority of nonabsorbable sutures has not been consistently found in randomized trials for midline closure and nonabsorbable sutures are associated with more prolonged wound pain and a higher incidence of suture sinus compared with synthetic absorbable suture. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Midline'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Knots'",
"    </a>",
"    below.) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Monofilament versus multifilament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic nonabsorbable monofilament sutures (eg, polyamide and polypropylene) are more resistant to serious infection than are multifilament sutures and natural fibers. Thus, the composition of the suture, as well as the structure, influences the rate of bacterial absorption and proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/8\">",
"     8",
"    </a>",
"    ]. This was illustrated in the following representative reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study designed to determine the risk of infection for different suture materials, synthetic nonabsorbable monofilament sutures of nylon, wire, and polypropylene were associated with less serious infection than multifilament and natural fiber sutures [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/9\">",
"       9",
"      </a>",
"      ]. This was determined by placing sutures in rabbit subcutaneous tissue; the tissue was then inoculated with staphylococcus.",
"     </li>",
"     <li>",
"      In another study, both braided silk and braided nylon absorbed similar numbers of bacteria, while monofilament sutures absorbed significantly less. Braided polyglycolic acid absorbed an intermediate number of bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/10\">",
"       10",
"      </a>",
"      ]. In this guinea pig study, sutures were placed in solutions containing bacteria and then the number of bacteria absorbed by each suture was quantified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sutures that are coated with antimicrobial compounds have been found in various studies to decrease infection rates in midline surgical wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/11\">",
"     11",
"    </a>",
"    ]. In a randomized trial, polyglactin 910 suture coated with triclosan performed technically as well as standard coated polyglactin 910 suture, and seemed to reduce the risk of infection. Another study found that triclosan-coated polyglactin 910 suture decreased infection rates compared with polydioxanone (PDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multifilament sutures generally provide greater knot security than monofilament sutures. Sutures usually are weakest at the knot and knot strength depends upon a number of factors (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Knots'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Needles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many types of needles are available, most are designed for very special suturing needs. Needles are classified according to shape, caliber, degree of curvature, type of point, and how suture is attached (swaged or threaded) (",
"    <a class=\"graphic graphic_figure graphicRef54201 \" href=\"UTD.htm?13/5/13395\">",
"     figure 1",
"    </a>",
"    ). Most surgeons use only a few needle types. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H18#H18\">",
"     \"Closure of skin wounds with sutures\", section on 'Needles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Straight or curved",
"    </span>",
"    &nbsp;&mdash;&nbsp;Straight needles are used primarily for skin closure. They are of the cutting variety and are designed to be handheld. Curved needles require a needle driver. They are characterized by the diameter of their arc, degree of curvature, and caliber. Degree of curvature is one-fourth, three-eighths, one-half, and five-eighths of a circle. Selection of size and curvature depends upon the tissue to be sutured and the depth of dissection. The greater the curvature, the easier it is to manipulate the needle in deep or confined spaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle caliber is dependent upon the wire diameter from which the needle is made. These are defined as fine, medium, and heavy. Medium needles, which are sometimes called general closure needles, have utility in most tissues and are especially useful for pedicles and fascia. Fine needles are sometimes called intestinal needles because of their frequent use in gastrointestinal surgery. They are commonly used for delicate or thin tissue, small pedicles, and blood vessels. The heavy needles are often referred to as hernia needles. They are designed for use on fascia, ligaments, and other dense tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Point",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most abdominal incisions can be closed with one-half or five-eighths circle, taper point, general closure needles. Hernia needles may be used if the fascia is thickened or scarred. A cutting needle is rarely necessary for standard closures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Taper &mdash; Taper point needles are atraumatic. They create the smallest holes because the tissues are stretched and can retract around the suture. These are the most commonly employed needles and have utility in all tissues except skin.",
"     </li>",
"     <li>",
"      Blunt &mdash; Taper point needles can also be blunted. Blunt needles may give an extra measure of protection to both surgical personnel and patients from exposure to blood-borne pathogens because penetration of the skin is less likely even when penetration of gloves occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/13\">",
"       13",
"      </a>",
"      ]. Glove punctures and finger sticks with surgical needles account for up to 80 percent of accidental exposures to body fluids and potentially serious pathogens such as hepatitis B, hepatitis C, and HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/14\">",
"       14",
"      </a>",
"      ]. Double gloving also reduces exposure risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"       \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"       \"Management of healthcare personnel exposed to HIV\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Blunt needles may be used to close fascia satisfactorily but, because of the blunt tip, they do not immediately pierce the tissue and extra force is usually needed [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/15\">",
"       15",
"      </a>",
"      ]. On occasion, the surgeon may have to change to a traditional taper point or cutting needle.",
"     </li>",
"     <li>",
"      Cutting &mdash; Cutting needles have at least two honed edges and are used in dense or scarred tissue. Care must be taken with cutting needles to prevent laceration of tissue and accidental cuts to surgical personnel. The conventional cutting needle has three sharpened edges on its concave surface. It cuts tissue easily in the direction of the pull of the needle.",
"     </li>",
"     <li>",
"      Reverse cutting &mdash; A reverse cutting needle has a cutting edge on its convex surface. It generally cuts tissue away from the pull of the needle. Although it may prevent accidental cutting through the tissue edges, it will produce larger holes. These needles are useful for the placement of retention sutures.",
"     </li>",
"     <li>",
"      Free versus swaged &mdash; A free needle must be threaded though an eyelet while swaged needles are a single unit with the suture attached directly. The swaged needles may have the sutures attached to needles permanently or in a way that allows the needle to be pulled off with a gentle tug. The latter are known as control release or \"pop-off\" needles and may save time when numerous interrupted sutures are necessary. Swaged needles cause less tissue injury because they are smaller and always remain sharp. There is less chance of metal fatigue since they are disposable. Less handling and manipulation is needed with swaged needles, which may lower the risk of glove punctures and needle sticks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     KNOTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secure knots are critical for a strong closure. Most suture failures occur at the knot. Knot security is a function of how the loops and throws are configured, as well as the type and size of the suture.",
"   </p>",
"   <p>",
"    Many studies have been performed to determine which sutures have the best knot security, but results are mixed. It appears that braided suture consistently tends to have better knot security compared with monofilament suture when the same size, suture and number of knots are used. &nbsp;",
"   </p>",
"   <p>",
"    In most situations, a single strand of suture should be tied to a single strand. Tying a single strand of suture to a double strand of suture may reduce knot security [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/16\">",
"     16",
"    </a>",
"    ].This is especially important if the suture will significantly experience tension, such as with fascia closure.",
"   </p>",
"   <p>",
"    There is no benefit to the use of a surgeon&rsquo;s knot (a double throw in the first loop) over a square knot (",
"    <a class=\"graphic graphic_figure graphicRef74576 \" href=\"UTD.htm?16/18/16672\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/17\">",
"     17",
"    </a>",
"    ]. The primary benefit of a square knot is that it becomes tighter when the ends of the suture are pulled [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/17\">",
"     17",
"    </a>",
"    ]. Although knots are the weakest part of the suture, square knots maintain 90 percent of the tensile strength of untied sutures. If nonidentical sliding knots are used, then six throws are needed for adequate knot security [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Knots always provide space in which bacteria can become enmeshed and therefore are the most common site of sinus formation. Early attempts to exploit greater tensile strength of nonabsorbable sutures were thwarted by the frequency of suture sinuses when natural fiber multifilament sutures were used. The risk of sinus formation may approach 80 percent if a contaminated wound is closed with natural multifilament suture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lower risk of suture sinus formation with synthetic suture was illustrated in a study that compared continuous closure using polydioxanone (PDS) with interrupted closure using braided silk in clean and contaminated abdominal wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/19\">",
"     19",
"    </a>",
"    ]. The incidence of sinus formation was 1.3 percent in the PDS group compared with 7.1 percent in the silk group. Also, sinus formation following use of PDS healed within one week after percutaneous drainage alone without removal of the suture, whereas sinus formation associated with braided silk required excision of the sinus tract and removal of the infected suture. Wound dehiscence, early wound infection, and incisional hernia did not differ significantly between the two groups.",
"   </p>",
"   <p>",
"    Additionally, the use of absorbable suture may eliminate palpation of the knot through the skin, a potentially distressing problem in thin patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WOUND CLOSURE TECHNIQUE BY LAYER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of closure of the abdominal wall is a critical aspect of an effective incision closure, in addition to choice of suture material. Layered closure is described as the separate closure of the individual component of the abdominal wall, specifically the peritoneum and distinct musculoaponeurotic layers, whereas mass closure is the closure of all layers of the abdominal wall (except the skin) as a single structure. An evidence-based review identified three separate metaanalyses, each of which found that mass closure was associated with a lower incidence of incisional hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/6,20-22\">",
"     6,20-22",
"    </a>",
"    ]. In addition to mass closure, this review determined that the optimal method of abdominal wall closure is mass closure using absorbable suture in a simple running technique with a suture length to wound length ratio of 4 to 1. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Mass closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Peritoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical closure of the peritoneum does not impact incision strength or healing. There is overwhelming evidence from randomized trials that peritoneal closure is unnecessary because the peritoneum reepithelializes within 48 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Furthermore, peritoneal closure results in more advanced adhesion formation at the time of a subsequent procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also, there are insufficient data to suggest that aggressive peritoneal lavage is beneficial if there is no gross contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/26\">",
"     26",
"    </a>",
"    ]. Lavage may impede host defenses and spread previously-localized infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fascia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fascia is the most critical layer because this tissue provides the greatest wound tensile strength during healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tensile strength of the fascial wound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory process at the wound edge produces collagenase, which assists digestion of necrotic debris, but also results in lysis of collagen and partial digestion of fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/27\">",
"     27",
"    </a>",
"    ]. Collagenolytic activity peaks on the fifth postoperative day and extends up to 1 cm from the incision edge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/28\">",
"     28",
"    </a>",
"    ]. During these first few postoperative days, tensile strength of the sutured wound may actually decline by as much as 50 percent before a slow increase in tensile strength begins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tensile strength of a wound follows a characteristic nonlinear pattern and depends upon the synthesis of new connective tissue by fibroblasts. Adequate blood supply is critical to supply nutrients and oxygen. Wounds have less than 5 percent of the tensile strength of unwounded tissue in the first postoperative week, thus wound security is dependent solely upon suture that has been secured in strong healthy tissue. Maximum strength rarely, if ever, exceeds 80 to 90 percent of intact fascia. Fortunately, only 15 to 20 percent of maximum strength is necessary for normal daily activities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/30\">",
"     30",
"    </a>",
"    ]. Since return of tensile strength can take more than 70 days, sutures that maintain their strength for at least this length of time are preferred. Therefore, most surgeons select a delayed absorbable or nonabsorbable suture for abdominal wall closure. (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Materials'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fascial closure should reapproximate the wound edges without undue tension or tissue ischemia. Although interrupted closure has the advantage of not relying on the security of a single knot, this technique is associated with tissue ischemia due to an uneven distribution of tension. Fortunately, dehiscence due to knot slippage is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/31\">",
"     31",
"    </a>",
"    ]. Continuous closure distributes tension evenly along the entire length of the incision, allows better tissue perfusion, and saves time. A metaanalysis evaluating midline abdominal closure techniques supports closure of elective midline incisions with a continuous technique using slowly absorbable sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Midline'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The amount of suture used depends upon the size of each stitch (ie, distance from fascial edge) and stitch interval (ie, space between stitches). For continuous closure, the total length of the suture should be approximately four times the length of the incision [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/32\">",
"     32",
"    </a>",
"    ]. The use of a shorter length suture due to a reduced stitch size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stitch interval increases the risk of hernia formation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In a randomized trial, the incidence of hernia formation (9 versus 21.5 percent, respectively) was lower when the suture",
"    <span class=\"nowrap\">",
"     length/wound",
"    </span>",
"    length",
"    <span class=\"nowrap\">",
"     (SL/WL)",
"    </span>",
"    ratio was &ge;4 compared with &lt;4 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of whether interrupted or continuous closure is chosen, sutures should be placed about 10 mm from the fascial edge. Suture widths in excess of 10 mm may increase the magnitude of compressive forces on the tissue contained between the suture hole and fascial edge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/35\">",
"     35",
"    </a>",
"    ]. A randomized trial comparing long stitch width (&gt;10 mm) with shorter stitch width (5 to 8 mm) identified longer stitch width as an independent risk factor for the development of both incisional hernia and surgical site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/32\">",
"     32",
"    </a>",
"    ]. Incisional hernia occurred in 49 of 272 patients (18.0 percent) in the long stitch group and in 14 of 250 (5.6 percent) in the short stitch group.",
"   </p>",
"   <p>",
"    Retention sutures have traditionally been used in wounds thought to be at a high risk for dehiscence, but data consistently supporting this technique are lacking, and this technique is associated with increased wound complications and difficulty with ostomy placement and care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/36\">",
"     36",
"    </a>",
"    ]. However, placement of retention sutures is associated with decreased postoperative incisional pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mass closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mass closure may be performed in either a continuous or interrupted fashion. Mass closure significantly reduces the incidence of wound dehiscence and is performed by incorporating a small amount of subcutaneous fat, rectus muscle, rectus sheaths, transversalis fascia, and, optionally, the peritoneum. Techniques for mass closure include the Smead-Jones and continuous single or double loop closures.",
"   </p>",
"   <p>",
"    Continuous mass closure with nonabsorbable or slowly absorbable suture is safe and effective as interrupted techniques (",
"    <a class=\"graphic graphic_figure graphicRef51197 \" href=\"UTD.htm?18/6/18533\">",
"     figure 3",
"    </a>",
"    ). A trial comparing continuous fascial closure with interrupted Smead-Jones closure at the time of gynecologic surgery for benign or malignant disease reported no difference in the rate of wound complications, including dehiscence or hernia formation at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, studies in animals and humans have found continuous mass closures to be faster and more cost effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To perform the Smead-Jones closure, sutures are placed in a vertical mattress fashion. Continuous double loop mass closure may be superior to single loop mass closure. A study which compared the double and single loop mass closure in midline laparotomy wounds reported that wound dehiscence was zero with the continuous double loop closure technique compared with 8 percent for single loop mass closure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Subcutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recently, studies have found that there is no benefit to closure of the subcutaneous tissue as previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial wound disruption is often associated with wound seroma, hematoma, or infection. This suggests that closure of subcutaneous tissue may help prevent wound disruption by eliminating dead space, as opposed to increasing wound tensile strength. Meticulous attention to control of subcutaneous bleeding or the use of closed suction drainage can help prevent the development of hematoma or subcutaneous fluid collection and may have a similar effect on wound disruption as subcutaneous closure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/42,44\">",
"     42,44",
"    </a>",
"    ], although this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/45\">",
"     45",
"    </a>",
"    ]. Further randomized trials with stratification for incision type and other components of perioperative care (eg, use of antibiotics, type of suture material) are needed to examine these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closure of the skin may be performed with subcuticular suture, stainless steel staples, subcuticular absorbable staples, surgical tape, or wound adhesive glue.",
"   </p>",
"   <p>",
"    Despite popular belief, subcuticular closures do not always result in improved cosmesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/46\">",
"     46",
"    </a>",
"    ]. Subcuticular closure obviates the need to remove surgical staples, is more comfortable for the patient, and is less costly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/47\">",
"     47",
"    </a>",
"    ]. Subcuticular closure can be more difficult with vertical (as opposed to transverse incisions).",
"   </p>",
"   <p>",
"    Suture knots have potential disadvantages in subcuticular wound closure because they may cause tissue ischemia, act as a nidus for infection, and extrude through skin weeks after surgery. A barbed polyglycolic acid, polydioxanone, or polydioxanone suture (Quill&trade;, Contour Thread&trade;) is available that is self-anchoring and requires no knots [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/48\">",
"     48",
"    </a>",
"    ]. It has a similar cosmetic and safety profile as conventional suture, but avoids the drawbacks inherent to suture knots [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staples are fast, give an acceptable cosmetic result, are associated with a low rate of infection, and allow small portions of the wound to be opened easily, when needed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/49\">",
"     49",
"    </a>",
"    ]. Staple closure is less likely to obscure wound drainage and impending separation compared with subcuticular closures, but are more likely to be a source of postoperative pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/47\">",
"     47",
"    </a>",
"    ]. Staples are preferred for reentry incisions.",
"   </p>",
"   <p>",
"    Absorbable staples (eg, Insorb&trade;) potentially combine the benefits of subcuticular closure with the speed and precision of staple placement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/50\">",
"     50",
"    </a>",
"    ]. In a study that compared skin incision closure by absorbable subcuticular staples, cutaneous metal staples, and polyglactin 910 suture in a pig model, absorbable subcuticular staples induced a less severe inflammatory response in the early stages of healing.",
"   </p>",
"   <p>",
"    Surgical tape and adhesives are alternatives to suture or staples. In particular, use of tissue adhesives, such as octyl cyanoacrylate (Dermabond&reg;) and butylcyanoacrylate (Histoacryl&reg;), may potentially save time and has wound infection rates and cosmetic outcomes that are comparable with nonabsorbable monofilament sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/51\">",
"     51",
"    </a>",
"    ]. A systematic review supports these findings, but also noted that the tissue adhesives are associated with a small but significant increased rate of wound dehiscence which must be considered when choosing the closure method [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/52\">",
"     52",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=see_link\">",
"     \"Superficial wound repair with tissue adhesives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     WOUND CLOSURE BY INCISION TYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal wall incisions are generally closed using the principles described above; however, there are a few points specific to the type of incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Midline",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest placing the omentum beneath a longitudinal incision to reduce the risk of adhesions between bowel and the anterior abdominal wall. The posterior rectus sheath is included in the fascial closure to increase tensile strength of the closure.",
"   </p>",
"   <p>",
"    To minimize the risk of incisional hernia, elective midline abdominal closure (first operation or reoperation) should be performed using a continuous technique with slowly absorbable sutures. A metaanalysis of 14 randomized trials of midline fascial closure in 7711 patients compared the incidence of incisional hernia for elective abdominal wall closure performed with continuous versus interrupted closure, rapidly absorbable versus slowly absorbable and nonabsorbable versus slowly absorbable suture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapidly absorbable sutures included polyglactin 910 (Vicryl&trade;), and polyglycolic acid (Dexon&trade;). Slowly absorbable sutures included polydioxanone (PDS&trade;, MonoPlus&reg;) and polyglyconate + trimethylene carbonate (Maxon&trade;). Nonabsorbable sutures included polyamide (nylon), polypropylene (Prolene&trade;) and polyester (Ethibond&trade;) (",
"    <a class=\"graphic graphic_table graphicRef65396 \" href=\"UTD.htm?24/47/25340\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of incisional hernia was significantly higher in the interrupted compared with continuous closure group (12.6 versus 8.4 percent) regardless of the type of suture material used (ie, absorbable versus nonabsorbable).",
"     </li>",
"     <li>",
"      The incidence of incisional hernia was significantly lower for absorbable sutures compared with nonabsorbable sutures (6.1 versus 26.3 percent) regardless of suture technique (ie, continuous versus interrupted).",
"     </li>",
"     <li>",
"      The incidence of incisional hernia was significantly lower for slowly absorbable sutures compared with rapidly absorbable sutures (8.1 verus 10.8 percent) regardless of suture technique (ie, continuous versus interrupted).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No conclusions could be drawn regarding optimal closure techniques for abdominal closure in an emergency setting.",
"   </p>",
"   <p>",
"    Since this metaanalysis, another trial randomly assigned 456 patients to closure of the midline abdominal fascia to nonabsorbable (polypropylene; Prolene&reg;) or absorbable (polydioxanone; PDS&trade;) suture material. In contrast, there were no significant differences in the incidence of incisional hernia or secondary outcomes measures between the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/53\">",
"     53",
"    </a>",
"    ]. This trial included both emergent and elective cases and did not stratify the analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Transverse",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pfannenstiel and Cherney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pfannenstiel and Cherney incisions are closed in a similar manner. The rectus muscles will usually approximate themselves, but if rectus diastasis is present, the muscles can be pulled to the midline with several loosely tied absorbable sutures. The aponeurosis is closed with interrupted or continuous suture. Both absorbable and nonabsorbable sutures have been used for closure; the author prefers absorbable running 2-0 suture because the risk of hernia formation is small. Skin can be reapproximated by any method. A subcuticular technique using 4-0 suture is easily performed since the edges are readily brought together.",
"   </p>",
"   <p>",
"    The only difference for the Cherney incision is the need to reattach the tendons to the lower aponeurosis of the anterior rectus sheath rather than to the periosteum of the symphysis directly. The author uses horizontal mattress sutures of 2-0 permanent suture material; delayed absorbable sutures are an alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Maylard incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the Maylard incision, oozing from the cut muscle and extensive tissue fluid collection may rarely be significant enough to warrant placement of a closed suction drainage system under the fascia. The drain is brought out through a stab wound separate from the incision. The fascia may then be closed with interrupted or continuous sutures, usually of 1 or 0 suture caliber. Permanent or delayed absorbable suture is preferred and a mass closure technique can be used. The author closes the fascia with running permanent suture of 0 suture caliber in a mass technique and closes the skin using a subcuticular technique with absorbable 4-0 suture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Oblique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oblique incisions are muscle-splitting, therefore the muscles reapproximate by their own contraction when anesthetic paralysis resolves. The wound would likely heal with skin closure only; however, we suggest a deep simple closure. The internal oblique and transversus abdominis are approximated with loosely tied absorbable sutures spaced 1 cm apart in the internal oblique layer. The external oblique aponeurosis can be closed with interrupted or continuous 2-0 absorbable sutures. The skin can be closed by any method. When oblique incisions are used in the face of intraabdominal infection, delayed primary closure should be considered (",
"    <a class=\"graphic graphic_figure graphicRef57035 \" href=\"UTD.htm?17/55/18296\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/54\">",
"     54",
"    </a>",
"    ]. Alternatively, the skin can be closed with staples so that the incision can be easily be reopened, as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DRAINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to closure, it may be necessary to place temporary drainage systems. Drains are categorized as passive or active, meaning that they rely upon gravity or negative pressure suction, respectively. Examples of passive drains include the Penrose drain, Foley catheter, Word catheter, and Mallencot catheter. Active drains may be open (eg, Salem sump) or closed systems (eg, Jackson-Pratt). One disadvantage of open systems is the potential for bacterial contamination of the tubing. Therefore, most surgeons prefer closed systems with negative pressure suction. Because closed suction systems (",
"    <a class=\"graphic graphic_figure graphicRef59098 \" href=\"UTD.htm?32/56/33667\">",
"     figure 5",
"    </a>",
"    ) require smaller incisions, herniation is uncommon.",
"   </p>",
"   <p>",
"    The primary indication for the placement of a drain is the prevention of fluid collection and subsequent infection. Procedures frequently associated with large collections of blood and serum (eg, hepatic, pancreatic surgery) may benefit from prophylactic drainage. Drains are placed adjacent the injured tissue (eg, liver, pancreas) or in the vicinity of an anastomosis at risk for leakage (ie, choledochoenteric, pancreaticoenteric). Other procedures that may require drainage include radical pelvic surgery, entry into the space of Retzius, or muscle splitting incisions. Randomized trials have found that closed drainage of the subcutaneous tissue did not improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the value of prophylactic drains remains controversial. Complications from drains may include infection, hemorrhage, kinking, and hernia formation. Good surgical technique with adequate hemostasis, the elimination of dead space, and the use of prophylactic antibiotics obviates the need for drains in most patients.",
"   </p>",
"   <p>",
"    The placement of drains in contaminated incisions may increase the incidence of wound infection. In clean wounds, antibiotic prophylaxis and drains are equally effective in preventing wound infection. Similarly, the placement of a drain in the vaginal cuff following hysterectomy prevents febrile morbidity, but is no more effective than prophylactic antibiotics in the prevention of cuff cellulitis or abscess.",
"   </p>",
"   <p>",
"    Drains are also sometimes placed as a means to irrigate a wound with antibiotic or other solutions. Irrigation of wounds with antibiotics may lower the incidence of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/55\">",
"     55",
"    </a>",
"    ]. However, antibiotic solutions are toxic to the cellular elements necessary for healing. For this reason, delayed closure of an abdominal incision with or without the use of negative pressure wound system is an alternative to irrigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drains should be placed through a small incision separate from the primary incision (",
"    <a class=\"graphic graphic_figure graphicRef81437 \" href=\"UTD.htm?30/31/31216\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/1\">",
"     1",
"    </a>",
"    ]. The drain should have a direct path to prevent kinking and subsequent obstruction. Care must be taken to avoid injury to the abdominal wall vessels (eg, epigastric), which can lead to significant bleeding. A stab wound involving the rectus sheath must be adequate to prevent kinking of the drain and to allow its removal, but not so large that a hernia may form. Normally, an incision greater than 5 mm but less than 10 mm is ideal. Care must also be taken to avoid suturing the drain to the fascia during closure. Once placed, the drain should be properly dressed and placed in a position that avoids traction and potential fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/56\">",
"     56",
"    </a>",
"    ] .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DRESSINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sterile dressing should be used to protect the wound for 24 to 48 hours postoperatively. Although the dry sterile dressing has been a standard for decades, wounds heal better if kept in a moist environment. Therefore, modern film dressings that are impermeable to fluid and bacteria but allow passage of moisture vapor may be preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/1,57\">",
"     1,57",
"    </a>",
"    ]. A study of semiocclusive dressings in over 3600 surgical patients reported faster wound healing, decreased pain, and less scarring compared with conventional dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/57\">",
"     57",
"    </a>",
"    ]. The semiocclusive dressing permitted visual assessment of the wound and promoted patient comfort, but did not increase the frequency of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Hydrocolloid dressings have also been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10633/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H456665430#H456665430\">",
"     \"Basic principles of wound management\", section on 'Common dressings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The suture chosen for closure should be absorbable and have a caliber that will provide adequate strength to the wound while minimizing foreign body content. Multifilament sutures provide better knot strength but are more prone to infection and sinus formation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sutures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most abdominal incisions can be closed with one-half or five-eighths circle, taper point, general closure needles. Hernia needles can be used if the fascia is thickened or scarred. A cutting needle is rarely needed for standard closures. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Needles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuous mass closure is the ideal closure method using using a suture length to wound length ratio of 4:1 in a simple running technique. The tissue should be reapproximated with low tension to prevent ischemia. A single strand should be tied to another single strand using a square knot or surgeon's knot. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fascia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Knots'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not closing the peritoneum, as this appears to confer no benefit (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Peritoneum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To reduce the incidence of incisional hernia following elective midline abdominal closure (first time closure or repeat closure), we recommend a continuous suture technique using slowly absorbable monofilament suture (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The optimal closure technique in the emergency setting has not been defined. The fascia of non-midline abdominal incisions can be closed in a similar fashion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H16#H16\">",
"       \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Suture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There appears to be no benefit to subcutaneous closure. Good surgical technique with adequate hemostasis and the use of prophylactic antibiotics obviates the need for drains in most patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Subcutaneous'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Drains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staples, subcuticular suture, and tissue adhesives are appropriate for skin closure; the wound should be covered with a semipermeable film or hydrocolloid dressing. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Skin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Dressings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/1\">",
"      Pearl ML, Rayburn WF. Choosing abdominal incision and closure techniques: a review. J Reprod Med 2004; 49:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/2\">",
"      Yaltirik M, Dedeoglu K, Bilgic B, et al. Comparison of four different suture materials in soft tissues of rats. Oral Dis 2003; 9:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/3\">",
"      MADSEN ET. An experimental and clinical evaluation of surgical suture materials. Surg Gynecol Obstet 1953; 97:73.",
"     </a>",
"    </li>",
"    <li>",
"     Adapted from Ethicon Wound Closure Manual. Sommerville, NJ, Ethicon, Inc., 2005. file://surgery.uthscsa.edu/pediatric/training/woundclosuremanual.pdf (Accessed on June 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/5\">",
"      Hodgson NC, Malthaner RA, Ostbye T. The search for an ideal method of abdominal fascial closure: a meta-analysis. Ann Surg 2000; 231:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/6\">",
"      van 't Riet M, Steyerberg EW, Nellensteyn J, et al. Meta-analysis of techniques for closure of midline abdominal incisions. Br J Surg 2002; 89:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/7\">",
"      Diener MK, Voss S, Jensen K, et al. Elective midline laparotomy closure: the INLINE systematic review and meta-analysis. Ann Surg 2010; 251:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/8\">",
"      Thiede A, Jostarndt L, L&uuml;nstedt B, Sonntag HG. [Controlled experimental histological and microbiological studies on the inhibitory effect of polyglycolic acid sutures in infections]. Chirurg 1980; 51:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/9\">",
"      Alexander JW, Kaplan JZ, Altemeier WA. Role of suture materials in the development of wound infection. Ann Surg 1967; 165:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/10\">",
"      McGeehan D, Hunt D, Chaudhuri A, Rutter P. An experimental study of the relationship between synergistic wound sepsis and suture materials. Br J Surg 1980; 67:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/11\">",
"      Ford HR, Jones P, Gaines B, et al. Intraoperative handling and wound healing: controlled clinical trial comparing coated VICRYL plus antibacterial suture (coated polyglactin 910 suture with triclosan) with coated VICRYL suture (coated polyglactin 910 suture). Surg Infect (Larchmt) 2005; 6:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/12\">",
"      Justinger C, Moussavian MR, Schlueter C, et al. Antibacterial [corrected] coating of abdominal closure sutures and wound infection. Surgery 2009; 145:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/13\">",
"      Montz FJ, Fowler JM, Farias-Eisner R, Nash TJ. Blunt needles in fascial closure. Surg Gynecol Obstet 1991; 173:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/14\">",
"      Marcus R. Surveillance of health care workers exposed to blood from patients infected with the human immunodeficiency virus. N Engl J Med 1988; 319:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/15\">",
"      Nordkam RA, Bluyssen SJ, van Goor H. Randomized clinical trial comparing blunt tapered and standard needles in closing abdominal fascia. World J Surg 2005; 29:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/16\">",
"      Ivy JJ, Unger JB, Hurt J, Mukherjee D. The effect of number of throws on knot security with nonidentical sliding knots. Am J Obstet Gynecol 2004; 191:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/17\">",
"      van Rijssel EJ, Trimbos JB, Booster MH. Mechanical performance of square knots and sliding knots in surgery: comparative study. Am J Obstet Gynecol 1990; 162:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/18\">",
"      Cutler EC, Dunphy JE. The use of silk in infected wounds. N Engl J Med 1941; 224:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/19\">",
"      Iwase K, Higaki J, Tanaka Y, et al. Running closure of clean and contaminated abdominal wounds using a synthetic monofilament absorbable looped suture. Surg Today 1999; 29:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/20\">",
"      Weiland DE, Bay RC, Del Sordi S. Choosing the best abdominal closure by meta-analysis. Am J Surg 1998; 176:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/21\">",
"      Rucinski J, Margolis M, Panagopoulos G, Wise L. Closure of the abdominal midline fascia: meta-analysis delineates the optimal technique. Am Surg 2001; 67:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/22\">",
"      Ceydeli A, Rucinski J, Wise L. Finding the best abdominal closure: an evidence-based review of the literature. Curr Surg 2005; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/23\">",
"      Jenkins TR. It's time to challenge surgical dogma with evidence-based data. Am J Obstet Gynecol 2003; 189:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/24\">",
"      Tulandi T, Al-Jaroudi D. Nonclosure of peritoneum: a reappraisal. Am J Obstet Gynecol 2003; 189:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/25\">",
"      Komoto Y, Shimoya K, Shimizu T, et al. Prospective study of non-closure or closure of the peritoneum at cesarean delivery in 124 women: Impact of prior peritoneal closure at primary cesarean on the interval time between first cesarean section and the next pregnancy and significant adhesion at second cesarean. J Obstet Gynaecol Res 2006; 32:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/26\">",
"      Platell C, Papadimitriou JM, Hall JC. The influence of lavage on peritonitis. J Am Coll Surg 2000; 191:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/27\">",
"      Adamsons RJ, Musco F, Enquist IF. The chemical dimensions of a healing incision. Surg Gynecol Obstet 1966; 123:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/28\">",
"      Grillo HC, Gross J. Enzyme found in healing wound. Medical World News 1965; 6:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/29\">",
"      Foresman PA, Edlich RF, Rodeheaver GT. The effect of new monofilament absorbable sutures on the healing of musculoaponeurotic incisions, gastrotomies, and colonic anastomoses. Arch Surg 1989; 124:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/30\">",
"      DOUGLAS DM. The healing of aponeurotic incisions. Br J Surg 1952; 40:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/31\">",
"      Gislason H, Gr&oslash;nbech JE, S&oslash;reide O. Burst abdomen and incisional hernia after major gastrointestinal operations--comparison of three closure techniques. Eur J Surg 1995; 161:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/32\">",
"      Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length on wound complications after closure of midline incisions: a randomized controlled trial. Arch Surg 2009; 144:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/33\">",
"      Israelsson LA, Jonsson T. Closure of midline laparotomy incisions with polydioxanone and nylon: the importance of suture technique. Br J Surg 1994; 81:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/34\">",
"      Millbourn D, Israelsson LA. Wound complications and stitch length. Hernia 2004; 8:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/35\">",
"      Cengiz Y, Gislason H, Svanes K, Israelsson LA. Mass closure technique: an experimental study on separation of wound edge. Eur J Surg 2001; 167:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/36\">",
"      Wasiljew BK, Winchester DP. Experience with continuous absorbable suture in the closure of abdominal incisions. Surg Gynecol Obstet 1982; 154:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/37\">",
"      Orr JW Jr, Orr PF, Barrett JM, et al. Continuous or interrupted fascial closure: a prospective evaluation of No. 1 Maxon suture in 402 gynecologic procedures. Am J Obstet Gynecol 1990; 163:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/38\">",
"      Seid MH, McDaniel-Owens LM, Poole GV Jr, Meeks GR. A randomized trial of abdominal incision suture technique and wound strength in rats. Arch Surg 1995; 130:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/39\">",
"      Meeks GR, Nelson KC, Byars RW. Wound strength in abdominal incisions: a comparison of two continuous mass closure techniques in rats. Am J Obstet Gynecol 1995; 173:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/40\">",
"      Colombo M, Maggioni A, Parma G, et al. A randomized comparison of continuous versus interrupted mass closure of midline incisions in patients with gynecologic cancer. Obstet Gynecol 1997; 89:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/41\">",
"      Nasir GA, Baker KK. Continuous double loop closure for midline laparotomy wounds. Saudi Med J 2001; 22:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/42\">",
"      Cardosi RJ, Drake J, Holmes S, et al. Subcutaneous management of vertical incisions with 3 or more centimeters of subcutaneous fat. Am J Obstet Gynecol 2006; 195:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/43\">",
"      Paral J, Ferko A, Varga J, et al. Comparison of sutured versus non-sutured subcutaneous fat tissue in abdominal surgery. A prospective randomized study. Eur Surg Res 2007; 39:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/44\">",
"      Magann EF, Chauhan SP, Rodts-Palenik S, et al. Subcutaneous stitch closure versus subcutaneous drain to prevent wound disruption after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol 2002; 186:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/45\">",
"      Ramsey PS, White AM, Guinn DA, et al. Subcutaneous tissue reapproximation, alone or in combination with drain, in obese women undergoing cesarean delivery. Obstet Gynecol 2005; 105:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/46\">",
"      Nygaard IE, Squatrito RC. Abdominal incisions from creation to closure. Obstet Gynecol Surv 1996; 51:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/47\">",
"      Frishman GN, Schwartz T, Hogan JW. Closure of Pfannenstiel skin incisions. Staples vs. subcuticular suture. J Reprod Med 1997; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/48\">",
"      Murtha AP, Kaplan AL, Paglia MJ, et al. Evaluation of a novel technique for wound closure using a barbed suture. Plast Reconstr Surg 2006; 117:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/49\">",
"      Edlich RF, Becker DG, Thacker JG, Rodeheaver GT. Scientific basis for selecting staple and tape skin closures. Clin Plast Surg 1990; 17:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/50\">",
"      Fick JL, Novo RE, Kirchhof N. Comparison of gross and histologic tissue responses of skin incisions closed by use of absorbable subcuticular staples, cutaneous metal staples, and polyglactin 910 suture in pigs. Am J Vet Res 2005; 66:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/51\">",
"      Dowson CC, Gilliam AD, Speake WJ, et al. A prospective, randomized controlled trial comparing n-butyl cyanoacrylate tissue adhesive (LiquiBand) with sutures for skin closure after laparoscopic general surgical procedures. Surg Laparosc Endosc Percutan Tech 2006; 16:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/52\">",
"      Chow A, Marshall H, Zacharakis E, et al. Use of tissue glue for surgical incision closure: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Surg 2010; 211:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/53\">",
"      Bloemen A, van Dooren P, Huizinga BF, Hoofwijk AG. Randomized clinical trial comparing polypropylene or polydioxanone for midline abdominal wall closure. Br J Surg 2011; 98:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/54\">",
"      Gottrup F, Fogdestam I, Hunt TK. Delayed primary closure: an experimental and clinical review. J Clin Surg 1982; 1:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/55\">",
"      Farnell MB, Worthington-Self S, Mucha P Jr, et al. Closure of abdominal incisions with subcutaneous catheters. A prospective randomized trial. Arch Surg 1986; 121:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/56\">",
"      Pesce C, Galvagno SM Jr, Efron DT, et al. Retained drains causing a bronchoperitoneal fistula: a case report. J Med Case Rep 2011; 5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/57\">",
"      Rubio PA. Use of semiocclusive, transparent film dressings for surgical wound protection: experience in 3637 cases. Int Surg 1991; 76:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/58\">",
"      Holm C, Petersen JS, Gr&oslash;nboek F, Gottrup F. Effects of occlusive and conventional gauze dressings on incisional healing after abdominal operations. Eur J Surg 1998; 164:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10633/abstract/59\">",
"      Ravenscroft MJ, Harker J, Buch KA. A prospective, randomised, controlled trial comparing wound dressings used in hip and knee surgery: Aquacel and Tegaderm versus Cutiplast. Ann R Coll Surg Engl 2006; 88:18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10633=[""].join("\n");
var outline_f10_24_10633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sutures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2858619\">",
"      - Size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2858611\">",
"      - Synthetic versus natural",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Absorbable versus nonabsorbable",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Monofilament versus multifilament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Needles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Straight or curved",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diameter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Point",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      KNOTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WOUND CLOSURE TECHNIQUE BY LAYER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Peritoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fascia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tensile strength of the fascial wound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mass closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Subcutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      WOUND CLOSURE BY INCISION TYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Midline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Transverse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pfannenstiel and Cherney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Maylard incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Oblique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DRAINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DRESSINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/4\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/4|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/5/13395\" title=\"figure 1\">",
"      Types of surgical needles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/18/16672\" title=\"figure 2\">",
"      Surgical knots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/6/18533\" title=\"figure 3\">",
"      Mass closure of abdominal incisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/55/18296\" title=\"figure 4\">",
"      McBurney abdominal incision and closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/56/33667\" title=\"figure 5\">",
"      Tubes for closed suction drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/31/31216\" title=\"figure 6\">",
"      Drain placement at surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/4|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/43/33467\" title=\"table 1\">",
"      Types of suture material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/47/25340\" title=\"table 2\">",
"      Characteristics suture material",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=related_link\">",
"      Superficial wound repair with tissue adhesives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_24_10634="Antiplatelet therapy after coronary artery stenting";
var content_f10_24_10634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiplatelet therapy after coronary artery stenting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/24/10634/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/24/10634/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery stents, particularly drug-eluting stents (DES), are used in the majority of patients who undergo percutaneous coronary intervention (PCI) to improve symptoms in patients with obstructive coronary artery disease. They function both to prevent abrupt closure of the stented artery soon after the procedure as well as to lower the need for repeat revascularization compared to balloon angioplasty alone (formerly referred to as percutaneous transluminal coronary angioplasty).",
"   </p>",
"   <p>",
"    Stent restenosis and stent thrombosis are potential complications of coronary artery stenting; their incidence is highest in the first year after PCI. Stent restenosis, which occurs more frequently with bare metal stents (BMS) than drug-eluting stents (DES), may occasionally present as an acute myocardial infarction.",
"   </p>",
"   <p>",
"    Stent thrombosis is an uncommon but serious complication that often presents as death and is almost always accompanied by myocardial infarction (MI), usually with ST-segment elevation. The cumulative incidence of stent thrombosis appears to occur with similar frequency in patients with BMS or DES, as long as patients are treated with dual antiplatelet therapy (DAPT) for the recommended duration for the particular stent. DAPT (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus platelet P2Y12 receptor blocker) significantly lowers the risk of stent thrombosis. In the absence of DAPT, the period of high risk for stent thrombosis is longer with DES than BMS due to a delay in neointimal coverage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H19#H19\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Comparison of DES and BMS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H12#H12\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Very late stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the use of antiplatelet therapy to reduce the risk of adverse outcomes such as MI or death after stenting. Issues related to the incidence and timing of stent thrombosis and the use of antiplatelet drugs in the periprocedural period, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H2#H2\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF STENT THROMBOSIS AND RESTENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a successful procedure, coronary stents can fail to maintain vessel patency due to stent thrombosis or stent restenosis. Stent thrombosis is an abrupt thrombotic occlusion of a previously patent stent.&nbsp;It is a serious complication that presents as sudden death or myocardial infarction in most patients.&nbsp;Despite successful repeat revascularization, the six-month mortality is high. Earlier randomized clinical trials that evaluated the frequency of stent thrombosis did not use a uniform definition in their protocols, leading to difficulty in comparing the different studies. The following definitions were used in most studies and will be referred to as the historical definition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Events occurring within the first 30 days were considered to represent acute or subacute stent thrombosis if there was angiographic vessel occlusion, any new Q-wave MI in an area supplied by the stented vessel,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unexplained death from a cardiac cause.",
"     </li>",
"     <li>",
"      Events occurring after 30 days were considered to represent late stent thrombosis if there was a new MI with occlusion of the stented artery on angiography. This definition underestimates the incidence of stent thrombosis since unexplained MI in the territory of the stented vessels and late deaths, which may have been due to stent thrombosis, were usually not included.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another problem is that, in some clinical trials, stent thrombosis occurring in a patient who had previously undergone repeat target lesion revascularization was not counted. Since this is more likely to occur in a patient with a BMS due to the more frequent need for repeat revascularization, there is a potential for bias against DES.",
"   </p>",
"   <p>",
"    In an attempt to standardize the definition, an academic research consortium (ARC) proposed the following criteria for stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Definite",
"      </strong>",
"      &mdash; Angiographic confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or ECG signs of acute ischemia or typical rise and fall of in cardiac biomarkers within 48 hours of angiography",
"      <strong>",
"       OR",
"      </strong>",
"      pathologic confirmation of stent thrombosis determined at autopsy or from tissue obtained following thrombectomy.",
"     </li>",
"     <li>",
"      <strong>",
"       Probable",
"      </strong>",
"      &mdash; Unexplained death occurring within 30 days after the index procedure, or a myocardial infarction occurring at any time after the index procedure that was documented by ECG or imaging to occur in an area supplied by the stented vessel in the absence of angiographic confirmation of stent thrombosis or other culprit lesion.",
"     </li>",
"     <li>",
"      <strong>",
"       Possible",
"      </strong>",
"      &mdash; Unexplained death occurring more than 30 days after the index procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the discussion that follows, studies will be identified as having used either the historical or the ARC definition. Most studies published after 2010 use only the ARC definition.",
"   </p>",
"   <p>",
"    Restenosis is a gradual re-narrowing of the stented segment that occurs mostly between 3 to 12 months after stent placement. It usually presents as recurrent angina but can present as acute myocardial infarction (MI) in approximately 10 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972717881\">",
"    <span class=\"h1\">",
"     PREVENTION OF PERIPROCEDURAL THROMBOTIC EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the periprocedural use of antithrombotic therapy, including antiplatelet therapy, are found elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H35#H35\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Summary and recommendations'",
"    </a>",
"    ), as are recommendations for their use at the time of percutaneous coronary intervention in patients with acute coronary syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H434346709#H434346709\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Invasive approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periprocedural factors such as poor stent expansion, edge dissections limiting inflow or outflow, or unaddressed significant proximal or distal lesions increase the risk of stent thrombosis. We recommend periprocedural strategies, such as appropriate vessel sizing, high-pressure deployment, and post-dilatation, ensuring absence of edge dissections and ensuring adequate inflow and outflow, that decrease the likelihood of these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of the use of intracoronary stents\", section on 'Optimal stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LONG-TERM ANTIPLATELET THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In almost all patients who receive an intracoronary stent, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a second antiplatelet agent, referred to as dual antiplatelet therapy (DAPT), is used for some period of time after stenting.&nbsp;While the optimal duration of DAPT after stenting with DES is not known, most of the evidence suggests that 12 months is a reasonable goal. Until ongoing studies, testing the hypothesis that a shorter duration is equally efficacious, are completed, our practice is to recommend at least 12 months of DAPT after placement of either bare metal or drug-eluting stents (BMS or DES) in patients not at high risk of bleeding and in whom surgery requiring discontinuation of DAPT is not anticipated. The minimum duration of uninterrupted therapy (ie, before which every effort to not stop therapy should be made) is four weeks for patients who receive BMS and six months for patients who receive DES.",
"   </p>",
"   <p>",
"    DAPT is typically the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , all of which are referred to as platelet P2Y12 receptor blockers. Clopidogrel and ticlopidine have been evaluated in patients with stable coronary artery disease, while prasugrel and ticagrelor have been studied in patients with acute coronary syndromes. Ticlopidine is rarely used because of its adverse hematologic side effects. The impact of antiplatelet therapy after stenting is assessed by evaluating outcomes associated with stent thrombosis such as death or myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1293704694\">",
"    <span class=\"h2\">",
"     Dual versus single antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of DAPT, as opposed to antiplatelet monotherapy, derived from the known tendency of blood to clot in the presence of many metals and the observations that the risk of thrombosis falls when the metal stent is covered by an endothelial layer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H11#H11\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Early and late stent thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H3#H3\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DAPT is expected to lower the risk of stent thrombosis during the period of time when the metal portion of the stent is exposed to circulating blood (ie, before complete endothelialization has occurred) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H5#H5\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Bare metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While most bare metal stents are significantly endothelialized by one month and completely endothelialized by three to six months, near complete or complete endothelialization of DES occurs later [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Numerous observations of incomplete endothelialization after six months exist and some studies have shown incomplete endothelialization after as long as five years after first-generation DES [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, for both BMS and DES, and in particular the latter, the optimal duration of DAPT is unknown in the individual patient.",
"   </p>",
"   <p>",
"    Early studies evaluated various antithrombotic regimens, including both antiplatelet and antithrombotic agents individually or together. In studies of patients who received BMS, the rate of stent thrombosis was significantly lower with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    than with aspirin alone or aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. For example, the efficacy of combined antiplatelet therapy was demonstrated in the STARS trial in which 1653 patients were randomly assigned to aspirin alone or in combination with warfarin or ticlopidine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/11\">",
"     11",
"    </a>",
"    ]. The primary end point included all clinical events reflecting stent thrombosis within 30 days: death, revascularization of the target lesion, angiographically documented thrombosis, or myocardial infarction. The rate of the primary end point was significantly lower with aspirin plus ticlopidine than with aspirin plus warfarin or aspirin alone (0.5 versus 2.7 or 3.6 percent, respectively). After one randomized trial demonstrated similar efficacy between ticlopidine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    but a better side effect profile with the latter, the use of ticlopidine declined dramatically; it is now rarely used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H4#H4\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Ticlopidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies that have compared dual to single antiplatelet therapy in stable patients who received DES. However, we believe the rationale for DAPT (as opposed to antiplatelet monotherapy) after DES implantation is strongly based on biologic plausibility, evidence of benefit in patients with BMS, and observations of adverse outcomes, including stent thrombosis, when DAPT is discontinued during the period of time when incomplete endothelialization is possible or probable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1293704686\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the optimal duration of DAPT is unknown, in part because few well performed studies have evaluated differing durations. Ongoing randomized trials such as ISAR SAFE and DAPT will provide additional information regarding the optimal duration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Based on the available evidence, we prescribe dual antiplatelet therapy (DAPT) for at least 12 months in stable patients treated with DES and in those treated with BMS for whom the bleeding risk is not high and in whom surgery is not anticipated. Patients with acute coronary syndromes should be treated with DAPT for at least 12 months irrespective of revascularization strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H1554043015#H1554043015\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Duration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9212252\">",
"    <span class=\"h3\">",
"     Bare metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best evidence regarding the optimal duration of DAPT in stable patients who receive BMS comes from the CREDO trial, in which 2116 patients were randomly assigned to a 300 mg loading dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or placebo prior to PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/18\">",
"     18",
"    </a>",
"    ]. All patients received clopidogrel 75 mg daily through day 28. From day 29 through 12 months, patients in the initial clopidogrel group received clopidogrel 75 mg daily and those in the control group received placebo. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    throughout the study. At one year, the risk of the composite primary outcome of death, MI, or stroke was significantly lower with continuation of clopidogrel (8.5 versus 11.5 percent; relative risk reduction 26.9, 95% CI 2.9-44.4). Indirect support for the use of DAPT for one year comes from the PCI-CURE trial of patients with acute coronary syndromes who underwent stenting with BMS. After one month of clopidogrel plus aspirin, patients were randomly assigned to aspirin plus clopidogrel or aspirin plus placebo for a mean of nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/19\">",
"     19",
"    </a>",
"    ]. Findings were similar to those in CREDO.",
"   </p>",
"   <p>",
"    In both trials, the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy increased over time, with no evidence of a plateau at one year (",
"    <a class=\"graphic graphic_figure graphicRef70192 \" href=\"UTD.htm?37/31/38397\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80138 \" href=\"UTD.htm?35/49/36637\">",
"     figure 2",
"    </a>",
"    ). Although neither trial assessed the specific outcome of stent thrombosis, both provide some evidence in favor of clopidogrel therapy for at least one year in patients with BMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2429024\">",
"    <span class=\"h3\">",
"     Drug-eluting stents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382324377\">",
"    <span class=\"h4\">",
"     One year or less",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no completed, optimally designed, randomized trials comparing differing durations of DAPT (of one year or less) in patients who received DES. Two randomized trials, both with important limitations, of patients undergoing PCI with DES have compared 12 months of DAPT to therapy of shorter duration. In each study, the primary composite end point included cardiac death, MI, stent thrombosis, and target vessel revascularization at one year:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EXCELLENT trial, 1443 patients undergoing stenting with a second generation DES (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"       \"Comparison of drug-eluting intracoronary stents\"",
"      </a>",
"      ) were randomly assigned to either 6 or 12 months of DAPT [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/20\">",
"       20",
"      </a>",
"      ]. While there was no significant difference in the rate of the primary combined end point of cardiac death, myocardial infarction, or ischemia-driven revascularization at 12 months (4.8 versus 4.3 percent, respectively), stent thrombosis (a secondary end point) tended to occur more frequently in the six-month group (0.9 versus 0.1 percent, p = 0.10). Similar findings were noted in an observational study of 2032 patients who received zotarolimus-eluting stents [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/21\">",
"       21",
"      </a>",
"      ]. The major limitation of this study was that it was underpowered for the outcomes of death or MI.",
"     </li>",
"     <li>",
"      In the RESET trial, 2117 patients were randomly assigned to either three months of DAPT following Endeavor zotarolimus-eluting stent or to 12 months of DAPT following other DES implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/22\">",
"       22",
"      </a>",
"      ]. There was no significant difference in the rate of the primary end point; the rates of stent thrombosis were 0.2 and 0.3 percent, respectively. The major limitation of this study was the use of differing DES in the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indirect support for at least one year of dual antiplatelet therapy in patients treated with DES comes from trials of BMS discussed in the section above. Additional support for DAPT for up to one year in patients who receive DES comes from studies that demonstrate an increased risk of late stent thrombosis (events between 30 days and one year) after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is withdrawn prematurely. However, the results of the PRODIGY trial (discussed below), which compared 6 to 24 months of DAPT (see",
"    <a class=\"local\" href=\"#H1382324384\">",
"     'Longer than one year'",
"    </a>",
"    below), raises the possibility that therapy for less than one year may be effective and safe.",
"   </p>",
"   <p>",
"    The three studies below, in which only first generation DES (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    ) were used, suggest that early discontinuation of platelet P2Y12 receptor blocker therapy increases the likelihood of stent thrombosis during the first year after DES placement. However, these studies do not inform us as to the optimal time to stop platelet P2Y12 receptor blocker therapy. For example, it is possible that the benefit of dual antiplatelet therapy, particularly considering the bleeding risk, may become small after six months.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective observational study of 3021 patients with DES who were followed for 18 months, discontinuation of platelet P2Y12 receptor blocker therapy during the first six months was the major predictor of stent thrombosis (hazard ratio 13.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/4\">",
"       4",
"      </a>",
"      ]. Discontinuation of platelet P2Y12 receptor blocker after six months did not predict the occurrence of ST.",
"     </li>",
"     <li>",
"      In a series of 38 cases of stent thrombosis occurring after DES implantation in 2974 consecutive patients, individuals with late stent thrombosis (between 1 and 12 months) were significantly more likely to have discontinued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (37 versus 11 percent in those without stent thrombosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/5\">",
"       5",
"      </a>",
"      ]. The mean duration between stent implantation and stent thrombosis was 153 days in patients with late stent thrombosis (events between 30 days and one year).",
"     </li>",
"     <li>",
"      The rate and consequences of prematurely discontinuing platelet P2Y12 receptor blocker therapy were evaluated in the PREMIER registry of MI patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/6\">",
"       6",
"      </a>",
"      ]. Among 500 DES treated MI patients, 68 (14 percent) had discontinued platelet P2Y12 receptor blocker therapy at 30 days. Those who discontinued medication were more likely to die during the next 11 months (7.5 versus 0.7 percent, 95% CI 1.3-60.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of late (events from one month to one year) or very late stent thrombosis (events after one year) in relation to discontinuation of one or both antiplatelet agents was evaluated in a review of 161 published cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/23\">",
"     23",
"    </a>",
"    ]. At the time of stent thrombosis, 19 patients were on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and thienopyridine, 94 were on aspirin only, 33 had aspirin and thienopyridine stopped simultaneously, and 15 had thienopyridine stopped first and then had aspirin discontinued. The following findings were noted in the 142 patients who had discontinued at least one drug:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 33 patients who stopped both antiplatelet agents simultaneously, the mean time to stent thrombosis was seven days.",
"     </li>",
"     <li>",
"      In 15 patients who had stopped a thienopyridine with no ill effect and then subsequently stopped",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , the median time to stent thrombosis was seven days from the discontinuation of aspirin.",
"     </li>",
"     <li>",
"      In the 48 patients who stopped both agents, 75 percent of cases occurred within 10 days.",
"     </li>",
"     <li>",
"      In 94 patients with prior discontinuation of thienopyridine but on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , the median time to event was 122 days. In this group, only 6 percent of cases occurred within 10 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk associated with the temporary discontinuation of DAPT within the first year was evaluated in ACDC study of 1622 individuals who received a DES and were placed on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and followed for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/24\">",
"     24",
"    </a>",
"    ]. The following observations were noted in the 171 patients who interrupted at least one antiplatelet drug.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuation was temporary in 111 patients, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      stopped in 31,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in 27, and both drugs in 53. The median duration of cessation was 7 days.",
"     </li>",
"     <li>",
"      The rate of acute coronary syndrome was not significantly different between those who discontinued and those who did not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this study suggests that temporary discontinuation is relatively safe, this study is limited due to small sample size.",
"   </p>",
"   <p>",
"    The causes of and predictors for premature discontinuation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H11#H11\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Early and late stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382324384\">",
"    <span class=\"h4\">",
"     Longer than one year",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very late stent thrombosis has been documented in patients who have received 12 months of dual antiplatelet therapy and then had platelet P2Y12 receptor blocker discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The following reports illustrate this point:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Very late stent thrombosis occurred (average of 16 months after implantation) in 10 patients with a BMS within a mean of 10 days after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 10,778 patients who underwent sirolimus-eluting stent placement, patients who discontinued both a platelet P2Y12 receptor blocker and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      had a significantly higher rate of stent thrombosis than those who continued both (2.1 versus 0.14 percent) in the time interval from 366 to 548 days after stent implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/29\">",
"       29",
"      </a>",
"      ]. When discontinuation of aspirin was taken into account, patients who discontinued a platelet P2Y12 receptor blocker but continued aspirin did not have an excess of stent thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two reports from randomized trials have attempted to evaluate the potential benefit of dual antiplatelet therapy beyond one year in patients who receive DES:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The REAL-LATE and ZEST-LATE trials randomly assigned 2701 patients, who had received DES and had been free of major adverse cardiac or cerebrovascular events and major bleeding for at least 12 months while on DAPT, to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or aspirin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/30\">",
"       30",
"      </a>",
"      ]. At two years (median follow-up of 19.2 months), there was no difference in the rate of the primary composite end point of MI or death from cardiac causes (1.8 percent versus 1.2 percent, respectively; hazard ratio, 1.65; 95% CI 0.80-3.36). In addition, there were no significant differences in the individual rates of stent thrombosis, MI, stroke, or death from any cause. Limitations of this trial include the inclusion of two underpowered trials, enrollment of predominantly low risk patients, and an unknown impact of a high rate of use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      during the first year after DES placement [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H10#H10\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cilostazol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The PRODIGY trial had a 4-by-2 factorial, open-label design in which 2013 patients were randomly assigned to one of four stent types (everolimus-eluting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      -eluting, zotarolimus-eluting, or bare metal stent) and treated with dual antiplatelet therapy for 30 days [",
"      <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients were then randomly assigned to either 6 or 24 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . Patients who received BMS who were randomly assigned to six months of DAPT were allowed to have clopidogrel stopped at 30 days. At two years, there was no difference in risk of the primary composite end point of all-cause death, MI, or cerebrovascular accident (10.0 versus 10.1 percent, respectively), the risk of any of the components of the primary outcome, or the risk of stent thrombosis. Shorter duration of therapy was associated with a trend toward a lower rate of type 3 major bleeding according to the BARC classification (1.5 versus 2.4 percent; hazard ratio 0.56, 95% CI 0.29-1.07) (",
"      <a class=\"graphic graphic_table graphicRef77838 \" href=\"UTD.htm?11/37/11869\">",
"       table 1",
"      </a>",
"      ). Limitations of the trial include its open-label design, randomization at 30 days rather than six months, and relatively small size. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evidence on the role of prolonged dual antiplatelet therapy comes from observational studies and meta-analyses of randomized DES versus BMS trials that evaluated either the rates of stent thrombosis or",
"    <span class=\"nowrap\">",
"     death/MI",
"    </span>",
"    after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was discontinued. Some studies showed evidence of benefit from treatment for longer than 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/33-35\">",
"     33-35",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/4,29,36,37\">",
"     4,29,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We conclude that the available evidence does not allow for a firm conclusion that there is a benefit from DAPT beyond one year. This issue is being addressed by the DAPT study, which will compare 12 and 30 months of dual antiplatelet therapy (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ) in stented patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with no risk factors for bleeding (such as prior gastrointestinal bleed or requirement for long-term oral anticoagulant) AND who are at increased risk of late stent thrombosis (such as those with complex PCI [including bifurcation lesions, long stents, multiple stents, suboptimal procedure outcome prior brachytherapy, or reduced left ventricular systolic function]), OR in whom stent thrombosis could be catastrophic (PCI of left main or proximal left anterior descending coronary arteries) are reasonable candidates for a recommendation of indefinite therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H19#H19\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Comparison of DES and BMS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal long-term antiplatelet strategy for patients with stent thrombosis while off DAPT is not known. Such individuals are at relatively high risk of recurrent thrombosis and should be considered for the reinstitution of DAPT for more than one year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9623?source=see_link&amp;anchor=H1128708655#H1128708655\">",
"     \"Coronary artery stent thrombosis: Clinical presentation and management\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9212529\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized trials of differing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    doses in",
"    <strong>",
"     stable",
"    </strong>",
"    patients who undergo PCI in the stent era. The issue of the optimal dose of aspirin was addressed in a prespecified subgroup analysis of the 17,263",
"    <strong>",
"     acute coronary syndrome",
"    </strong>",
"    patients who underwent early PCI in the CURRENT-OASIS 7 trial. There was no significant difference in the primary outcome (cardiovascular death, MI, or stroke at 30 days) between those who were randomly assigned for 30 days to a dose of 300 to 325 mg compared to those given 75 to 100 mg (4.1 versus 4.2 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/38\">",
"     38",
"    </a>",
"    ]. While there was no significant difference in the rate of major bleeding, the rate of minor bleeding was significantly higher in those who received the higher dose of aspirin (5.0 versus 4.3 percent; adjusted hazard ratio 1.18, 95% CI 1.03-1.36). In the analysis of all patients (n = 25,086) enrolled in the study, there was a small but significant increase in the rate of gastrointestinal bleeding with higher-dose aspirin (0.4 versus 0. 2 percent; p = 0.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/39\">",
"     39",
"    </a>",
"    ]. Based principally on CURRENT OASIS 7, our experts suggest that patients who have undergone elective stenting, irrespective of type of stent, be discharged on 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of aspirin.",
"   </p>",
"   <p>",
"    With regard to the dose of the platelet P2Y12 receptor blockers, we recommend doses used in the clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      -75 mg once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       Prasugrel",
"      </a>",
"      -10 mg once daily; for patients who weigh less than 60 kg, 5 mg once daily is the recommended dose.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       Ticagrelor",
"      </a>",
"      -90 mg twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9212890\">",
"    <span class=\"h2\">",
"     Patients taking oral anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our experts prefer BMS to DES in most patients who require long-term anticoagulation, in an attempt to reduce the exposure period to dual antiplatelet therapy. The management of patients taking oral anticoagulant and dual antiplatelet therapy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H24#H24\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1293704969\">",
"    <span class=\"h2\">",
"     Choice of stent type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although DES have been shown to improve outcomes in most patient and lesion subsets, the decision to place a drug-eluting stent (DES) rather than a bare metal stent (BMS) requires a careful assessment of the relative benefits and risks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The lower rate of repeat target vessel revascularization with a DES must be weighed against the costs of longer-term platelet P2Y12 receptor blocker therapy to prevent stent thrombosis, including an increase in the risk of bleeding while on long-term dual antiplatelet therapy and the potentially serious complications of noncompliance, which is often not predictable. Patients who are not likely to comply with a recommendation for one year of DAPT or who have a planned procedure that requires early cessation of antiplatelet therapy may be better candidates for a BMS than a DES [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to potential differences in the rates of stent thrombosis between differing DES, not all types have been directly compared. Some evidence suggests that everolimus-eluting stents have a lower rate than other stents. We do not believe that the evidence is strong enough to allow for a recommendation to prefer this stent over other second generation DES, but there is mounting evidence that the second generation DES have lower rates of stent thrombosis, especially beyond one year. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H616228991#H616228991\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Late and cumulative one-year stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407792\">",
"    <span class=\"h2\">",
"     Risk of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of bleeding on DAPT influences our recommendations for the duration of DAPT. Patients at high risk of bleeding or serious outcomes of bleeding while on DAPT include those with a history of transient ischemic attack (TIA) or stroke, age &ge;75 years, propensity to bleed (eg, recent trauma or surgery, recent or recurrent gastrointestinal bleeding, active peptic ulcer disease, severe hepatic impairment, body weight &lt;60 kg [for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ], or concomitant use of medications that increase risk [oral anticoagulants or nonsteroidal antiinflammatory drugs]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H21914160#H21914160\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For example, the REACH registry evaluated outcomes in 26,389 patients with coronary artery disease of whom 4460 (16.9 percent) had a prior history of stroke or TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with, compared to those without, prior",
"    <span class=\"nowrap\">",
"     stroke/TIA",
"    </span>",
"    had a higher risk of nonfatal hemorrhagic stroke (adjusted hazard ratio [HR] 1.76, 95% CI 1.00-3.08) and this risk was particularly high in patients receiving dual antiplatelet therapy (adjusted HR 5.21, 95 CI, 1.24-21.90).",
"   </p>",
"   <p>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9212435\">",
"    <span class=\"h1\">",
"     CAUSES OF DUAL ANTIPLATELET THERAPY FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest predictor of stent thrombosis is the premature cessations of DAPT. However, similar to many other preventative interventions, the optimal use of DAPT does not ensure that a patient will not experience stent thrombosis. For example, in an observational study of over 10,000 patients undergoing drug-eluting stent placement, those with early stent thrombosis were on dual antiplatelet therapy 86 percent of the time and those with late stent thrombosis were on dual antiplatelet therapy 57 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/29\">",
"     29",
"    </a>",
"    ]. In these patients, it is likely that one or more predisposing risk factors leading to a prothrombotic environment make it difficult for dual antiplatelet therapy to be fully effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Premature cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important predictor of early and late (at least up to six to nine months) stent thrombosis is absence of platelet P2Y12 receptor blocker therapy at the time of the event [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/34\">",
"     34",
"    </a>",
"    ]. In one report, the hazard ratio for premature discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was greater than 50 at nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, the following issues deserve particular attention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of noncompliance with recommendations for dual antiplatelet therapy must be assessed before the placement of a DES. This should include a discussion in reasonable detail with the patient and relevant caregivers of the pros and cons of DES versus BMS, the likelihood of compliance with recommendations for dual antiplatelet therapy for a minimum of one year, including issues of",
"      <span class=\"nowrap\">",
"       cost/insurance",
"      </span>",
"      coverage, assessment of the likelihood of noncardiac surgery in the next 12 months, and the consequences of premature cessation of therapy. Bare metal stents are preferred when compliance with dual antiplatelet therapy is uncertain.",
"     </li>",
"     <li>",
"      Office-based practitioners, such as primary care physicians or dentists, need to be properly educated about the importance of not discontinuing antiplatelet therapy unless absolutely necessary.",
"     </li>",
"     <li>",
"      Placement of BMS should be considered in patients in whom one or more risk factors for bleeding, particularly from the upper gastrointestinal tract, are present. In the event of major bleeding in a noncompressible area that begins in a patient on platelet P2Y12 receptor blocker therapy, the risks of platelet P2Y12 receptor blocker cessation must be weighed against the risk of prolonged bleeding. Consideration should be given to restarting platelet P2Y12 receptor blocker after bleeding has stopped or is controlled and to strategies to decrease the likelihood of bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=see_link\">",
"       \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rash, or other manifestations of a hypersensitivity reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , may develop in up to 4 percent of patients and possibly lead to drug discontinuation. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26232?source=see_link\">",
"       \"Hypersensitivity reactions to clopidogrel\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the unusual case in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    must be discontinued due to a procedure where there is a significant risk of uncontrollable bleeding, we discuss this decision with the physician performing the procedure to verify that continuing aspirin is truly a significant risk. There are very few situations that require discontinuing low-dose aspirin. As examples, aspirin can be continued with both CABG and cataract surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H26#H26\">",
"     \"Perioperative medication management\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cessation of antiplatelet therapy may be required for reasons such as urgent surgery or major bleeding. However, minor bleeding is also a risk factor for antiplatelet therapy cessation. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H29#H29\">",
"       \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clopidogrel resistance/nonresponse",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    is associated with stent thrombosis. The optimal approach to screening for or management of clopidogrel",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    is not known and we do not recommend either screening for clopidogrel",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    or using alternative antiplatelet strategies if",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    (in patients who are screened) as this strategy has not been shown to improve cardiovascular outcomes. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Possible adverse effect of proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal bleeding is a risk of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , particularly at the time of placement of an intracoronary stent when other potent antithrombotic therapy may be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H30#H30\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Gastrointestinal bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proton pump inhibitors (PPI) have been recommended for the prevention of gastrointestinal bleeding in patients at high risk for clinically important gastrointestinal bleeding. However, reports in 2008 and 2009 have raised concerns that some, but not necessarily all, PPIs interfere with the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to inhibit platelet function and thereby increase the likelihood of coronary artery stent thrombosis, myocardial infarction, or cardiovascular death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971641#H5971641\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H8#H8\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Primary prevention of aspirin induced GI bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H12#H12\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations for the use of PPIs in patients on dual antiplatelet therapy, including those patients who have undergone PCI, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971648#H5971648\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EARLY NONCARDIAC SURGERY OR GASTROINTESTINAL ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for emergent settings in which surgery cannot be delayed, we recommend that a platelet P2Y12 receptor blocker and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    be continued for at least the minimum recommended duration for each stent type and that elective noncardiac surgical procedures requiring discontinuation of dual antiplatelet be deferred. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6344?source=see_link&amp;anchor=H350963316#H350963316\">",
"     \"Elective noncardiac surgery after percutaneous coronary intervention\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be continued during this period if possible and not be discontinued without confirming absolute necessity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H26#H26\">",
"     \"Perioperative medication management\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar issues arise in patients scheduled to undergo gastrointestinal endoscopy. This matter is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554041279\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the prevention of stent thrombosis after coronary artery stenting in stable patients have been made in guidelines from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions",
"    <span class=\"nowrap\">",
"     (ACCF/AHA/SCAI)",
"    </span>",
"    in 2011 and the American College of Chest Physicians (ACCP) in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/24/10634/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA/SCAI",
"    </span>",
"    guideline makes the following strong recommendations for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 mg daily in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients receiving BMS for a non-ACS indication,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      should be given for a minimum of one month and ideally up to 12 months if the patient is at increased risk of bleeding.",
"     </li>",
"     <li>",
"      In patients receiving DES for a non-ACS indication,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      should be given for at least 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of two weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 ACCP guideline makes the following recommendations for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have undergone elective PCI with placement of BMS, a strong recommendation was made for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      for one month. For the subsequent 11 months, a weak recommendation was made for clopidogrel. After 12 months a strong recommendation was made for single antiplatelet therapy.",
"     </li>",
"     <li>",
"      For patients who have undergone elective PCI with placement of DES, a strong recommendation was made for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      for three to six months (with the shorter duration for &ndash;limus stents and the longer duration for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stents). A weak recommendation was made for clopidogrel for 12 months after the initial three to six months. After 12 months a strong recommendation was made for single antiplatelet therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/24/39298?source=see_link\">",
"       \"Patient information: Angioplasty and stenting for the heart (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following points apply to patients who undergo elective stenting. The use of dual antiplatelet therapy in individuals with an acute coronary syndrome who are treated with an intracoronary stent is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H434346709#H434346709\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Invasive approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of coronary artery stent thrombosis and its consequences of myocardial infarction (MI) or death are diminished by the use of dual antiplatelet therapy (DAPT) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a platelet P2Y12 receptor blocker compared to the use of aspirin alone. Premature cessation of aspirin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      P2Y12 receptor blocker is associated with increased risk and is the strongest predictor of stent thrombosis during the first six to nine months after stent placement. However, the optimal duration of such therapy after stenting with either bare metal stents (BMS) or drug-eluting stents (DES) is not known. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Long-term antiplatelet therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H19#H19\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Comparison of DES and BMS'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients undergoing",
"      <strong>",
"       elective",
"      </strong>",
"      stenting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is the preferred P2Y12 receptor blocker. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Long-term antiplatelet therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the recommendations for the duration of DAPT presented below differ slightly depending on the type of stent, the choice between BMS and DES should be made after taking into account the patient&rsquo;s ability to comply with recommendations for the duration of DAPT presented below and the higher risk of restenosis with BMS. (See",
"      <a class=\"local\" href=\"#H1293704969\">",
"       'Choice of stent type'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with either DES or BMS who are not at high bleeding risk and who do not have planned noncardiac surgery within one year, we recommend uninterrupted DAPT for one year (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1293704686\">",
"       'Duration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11407792\">",
"       'Risk of bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with BMS at high bleeding risk or who have planned noncardiac surgery within one year, we recommend a minimum of one month of uninterrupted DAPT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For such patients treated with DES, we recommend uninterrupted dual antiplatelet therapy for a minimum of six months (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1293704686\">",
"       'Duration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11407792\">",
"       'Risk of bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evidence to support the routine use of dual antiplatelet therapy beyond one year in patients who have received a DES is inconclusive. Our authors and reviewers consider such an approach after reviewing the relative benefits and burdens with their patients at one year. (See",
"      <a class=\"local\" href=\"#H1382324384\">",
"       'Longer than one year'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients who have sustained stent thrombosis while not taking DAPT, we suggest DAPT for longer than one year rather than shorter periods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      be continued indefinitely in all stented patients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H39#H39\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With regard to dosing (See",
"      <a class=\"local\" href=\"#H9212529\">",
"       'Dosing'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a daily dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      of 75 to 100 mg rather than higher doses (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      The dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is 75 mg daily.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/1\">",
"      Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/2\">",
"      Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/3\">",
"      Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation 2011; 124:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/4\">",
"      Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/5\">",
"      Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/6\">",
"      Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/7\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/8\">",
"      Ueda Y, Nanto S, Komamura K, Kodama K. Neointimal coverage of stents in human coronary arteries observed by angioscopy. J Am Coll Cardiol 1994; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/9\">",
"      Bergeron P, Rudondy P, Poyen V, et al. Long-term peripheral stent evaluation using angioscopy. Int Angiol 1991; 10:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/10\">",
"      Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/11\">",
"      Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/12\">",
"      Sch&ouml;mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/13\">",
"      Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/14\">",
"      Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/15\">",
"      Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/16\">",
"      Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010; 160:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/17\">",
"      Byrne RA, Schulz S, Mehilli J, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009; 157:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/18\">",
"      Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/19\">",
"      Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/20\">",
"      Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/21\">",
"      Kandzari DE, Barker CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/22\">",
"      Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/23\">",
"      Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/24\">",
"      Ferreira-Gonz&aacute;lez I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012; 60:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/25\">",
"      McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/26\">",
"      Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/27\">",
"      Ho PM, Fihn SD, Wang L, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J 2007; 154:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/28\">",
"      Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/29\">",
"      Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/30\">",
"      Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/31\">",
"      Berger PB. Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt. N Engl J Med 2010; 362:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/32\">",
"      Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/33\">",
"      Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/34\">",
"      van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/35\">",
"      Faxon DP, Lawler E, Young M, et al. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv 2012; 5:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/36\">",
"      Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008; 1:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/37\">",
"      Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009; 30:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/38\">",
"      Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/39\">",
"      CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/40\">",
"      Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/41\">",
"      Farb A, Boam AB. Stent thrombosis redux--the FDA perspective. N Engl J Med 2007; 356:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/42\">",
"      Ducrocq G, Amarenco P, Labreuche J, et al. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation 2013; 127:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/43\">",
"      Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/44\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/45\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/24/10634/abstract/46\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1572 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-210.101.131.232-F6895ED81D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10634=[""].join("\n");
var outline_f10_24_10634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS OF STENT THROMBOSIS AND RESTENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972717881\">",
"      PREVENTION OF PERIPROCEDURAL THROMBOTIC EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LONG-TERM ANTIPLATELET THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1293704694\">",
"      Dual versus single antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1293704686\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9212252\">",
"      - Bare metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2429024\">",
"      - Drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1382324377\">",
"      One year or less",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1382324384\">",
"      Longer than one year",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9212529\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9212890\">",
"      Patients taking oral anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1293704969\">",
"      Choice of stent type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407792\">",
"      Risk of bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9212435\">",
"      CAUSES OF DUAL ANTIPLATELET THERAPY FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Premature cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clopidogrel resistance/nonresponse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Possible adverse effect of proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EARLY NONCARDIAC SURGERY OR GASTROINTESTINAL ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1554041279\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1572\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1572|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/31/38397\" title=\"figure 1\">",
"      Clopidogrel outcome stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/49/36637\" title=\"figure 2\">",
"      Clopidogrel in CREDO one year",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1572|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/37/11869\" title=\"table 1\">",
"      BARC definition for bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9623?source=related_link\">",
"      Coronary artery stent thrombosis: Clinical presentation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6344?source=related_link\">",
"      Elective noncardiac surgery after percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26232?source=related_link\">",
"      Hypersensitivity reactions to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/24/39298?source=related_link\">",
"      Patient information: Angioplasty and stenting for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_24_10635="Risk cut off for Downs testing";
var content_f10_24_10635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The effect of selecting different risk cut-offs on triple test performance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Term risk cut-off",
"       </td>",
"       <td class=\"subtitle1\">",
"        Equivalent to maternal age cut-off of",
"       </td>",
"       <td class=\"subtitle1\">",
"        Detection rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False positive rate, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;1 in 250",
"       </td>",
"       <td>",
"        &ge;37",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 in 300",
"       </td>",
"       <td>",
"        &ge;36",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 in 350",
"       </td>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wald et al. Triple marker performance with gestational age estimated by ultrasound.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10635=[""].join("\n");
var outline_f10_24_10635=null;
var title_f10_24_10636="Survival estimates cancer";
var content_f10_24_10636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of studies comparing physicians' estimated survival to patients' actual survival",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Investigator",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median estimated survival,",
"weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median actual survival, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated survival/ actual",
"survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parkes 1972",
"       </td>",
"       <td>",
"        4.5*",
"       </td>",
"       <td>",
"        2.0*",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evans 1985",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        3.2&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heyse-Moore 1987",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forster 1988",
"       </td>",
"       <td>",
"        7&Delta;",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maltoni 1994",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maltoni 1995",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxenham 1998",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maltoni 1999",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Christakis 2000",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        5.3&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"     <br>",
"      * Values estimated from graph in paper.",
"      <br>",
"       &bull; Ratio of mean estimated survival/mean survival.",
"       <br>",
"        &Delta; 7 weeks calculated through statement in paper that survival was overestimated by 3.4 weeks on average.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10636=[""].join("\n");
var outline_f10_24_10636=null;
var title_f10_24_10637="Conditions causing hypothermia in children";
var content_f10_24_10637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F88088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F88088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions causing hypothermia in children by physiologic mechanism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Substrate deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Central nervous system conditions that disrupt hypothalamic and autonomic temperature regulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traumatic brain or spinal cord injury (including neurosurgical procedures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain tumors (eg, craniopharyngioma or astrocytoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital brain malformations (eg, anencephaly or absence of the corpus callosum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial dysautonomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generalized infection*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug overdose with agents that cause central nervous system depression and vasodilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotic agents (eg, chlorpromazine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressants (eg, amitriptyline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine or metabolic diseases that impair energy utilization or basal metabolic rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypopituitarism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menkes disease (Menkes kinky hair syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organic acidemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aminoacidemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased insensible losses due to disruption of skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermolysis bullosa and other weeping dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased calorie intake with decreased energy production and loss of insulating subcutaneous fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia nervosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyponatremia (eg, water intoxication)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Episodic spontaneous hypothermia with hyperhidrosis",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child abuse and maltreatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hypothermia is most frequently described in septic young infants or neonates and in patients with Gram negative sepsis.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Episodic spontaneous hypothermia with hyperhidrosis is a rare syndrome that is notable for hypothermia, diaphoresis, absence of shivering, and pallor without evidence of central nervous system abnormality or endocrinopathy. In addition to supportive care, episodes may respond to or be prevented by cyproheptadine.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Corneli HM. Accidental hypothermia. J Pediatr 1992; 120:671.",
"      </li>",
"      <li>",
"       Tunnessen WW, Roberts KB. Hypothermia. In: Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.8.",
"      </li>",
"      <li>",
"       Greenberg RA, Rittichier KK. Pediatric nonenvironmental hypothermia presenting to the emergency department: Episodic spontaneous hypothermia with hyperhidrosis. Pediatr Emerg Care 2003; 19:32.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10637=[""].join("\n");
var outline_f10_24_10637=null;
var title_f10_24_10638="Revasc hibernating myocardium";
var content_f10_24_10638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Improvement after revascularization in hibernating myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 288px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left ventricular (LV) ejection fraction before (pre-op) and eight weeks after coronary artery bypass surgery in patients with more than seven (group A) or seven or fewer viable segments (group B). A significant increase in LV ejection fraction was observed in patients in group A who had substantial viability before surgery. The analysis was based on a total of 15 segments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ragosta M, Beller G, Watson D, et al. Circulation 1993; 87:1630.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10638=[""].join("\n");
var outline_f10_24_10638=null;
var title_f10_24_10639="BCR ABL ratio leukemic cells";
var content_f10_24_10639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Approximate relationship between response, the putative number of leukemic cells, and the level of BCR-ABL transcripts in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 355px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When a complete cytogenetic response has been achieved, the (putative) number of residual Ph+ cells can be measured only with quantitative molecular methods. The figure highlights the importance of molecular methods in the evaluation of the response to treatment. However, the sensitivity of current methods may vary substantially and in any case, no method can detect the transcript at very low cellular levels. For this reason the term \"complete molecular response\" may be misleading, since it might erroneously be interpreted as an equivalent of complete disease eradication and cure. The term \"undetectable BCR-ABL\" may better describe the biologic situation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood: Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108:1809. Copyright &copy;2006 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_24_10639=[""].join("\n");
var outline_f10_24_10639=null;
